

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 7**
July 2012



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 7

July 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 7
July 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834		
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)	2428 (16.4%)		
MULTISOURCE	11953 (82.5%)	12187 (82.8%)	12328 (83.1%)		
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)	12187 (82.2%)		
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)		
EXCEPTIONS ¹	76 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES					
APPROVED	6	8	7		
NUMBER OF APPLICANTS	810	826	826		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL						
ABACAVIR SULFATE						
AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
ZIAGEN						
AB	+ VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL						
ACARBOSE						
AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL						
BUTAPAP						
+	MIKART	325MG;50MG	A089987 001	Oct 26, 1992	Jun	CRLD
PHRENILIN						
@	VALEANT	325MG;50MG	A087811 001	Jun 19, 1985	Jun	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
>A>	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012	Jul	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
SUSPENSION; ORAL						
CAPITAL AND CODEINE						
+	VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001		Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002	Jun	DISC
AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
TABLET; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL						
OXYCODONE AND ACETAMINOPHEN						
AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA
>A>	AA	ALVOGEN INC	A202677 001	Jul 26, 2012	Jul	NEWA
>A>	AA		A202677 002	Jul 26, 2012	Jul	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
----	-------------	--------------	-------------	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Apr	NEWA
----	----------------	--------------------	-------------	--------------	-----	------

AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
----	----------------	--------------------	-------------	--------------	-----	------

DIAMOX

@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC
---------------	--------------------	-------------	--------------	-----	------

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA INC	20%	A203853 001	Jun 21, 2012	Jun	NEWA
----	----------------	-----	-------------	--------------	-----	------

>A> ACLIDINIUM BROMIDE

>A> POWDER, METERED; INHALATION

>A> TUDORZA PRESSAIR

>A>	+ FOREST LABS INC	0.375MG/INH	N202450 001	Jul 23, 2012	Jul	NEWA
-----	-------------------	-------------	-------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997	May	CAHN
-----------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997	May	CAHN
-----------------------	-------	-------------	--------------	-----	------

@	800MG	A074891 002	Oct 31, 1997	May	CAHN
---	-------	-------------	--------------	-----	------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB	TOLMAR	0.3%	A200298 001	Jun 14, 2012	Jun	NEWA
----	--------	------	-------------	--------------	-----	------

DIFFERIN

AB	+ GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007	Jun	CFTG
----	--------------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

+ GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
--------------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@ TEVA PARENTERAL	3MG/ML	A078676 001	Jul 31, 2008	Mar	DISC
-------------------	--------	-------------	--------------	-----	------

@	3MG/ML	A076564 001	Jun 16, 2004	Jan	DISC
---	--------	-------------	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ SANDOZ INC	EQ 0.083% BASE;0.017%	A076867 001	Dec 21, 2006	Apr	DISC
--------------	-----------------------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA EQ 70MG BASE

N202344	001	Mar 12, 2012	Mar	NEWA
---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
----	----------------	------	---------	-----	--------------	-----	------

>A>	AB	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Jul	NEWA
-----	----	---------------	------	---------	-----	--------------	-----	------

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME 80 UNITS/ML

N020057	003	Apr 05, 1991	Mar	DISC
---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC 0.5MG

A077777	001	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

@ 1MG

A077777	002	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

@ 2MG

A077777	003	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

@ 3MG

A077777	004	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

>D>	AB	VINTAGE	0.5MG	A078442	001	Oct 15, 2007	Jul	DISC
-----	----	---------	-------	---------	-----	--------------	-----	------

>D>	AB		1MG	A078442	002	Oct 15, 2007	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		2MG	A078442	003	Oct 15, 2007	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		3MG	A078442	004	Oct 15, 2007	Jul	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>		@ VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007	Jul	DISC
-----	--	------------------	-------	---------	-----	--------------	-----	------

>A>		@	1MG	A078442	002	Oct 15, 2007	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

>A>		@	2MG	A078442	003	Oct 15, 2007	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

>A>		@	3MG	A078442	004	Oct 15, 2007	Jul	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726	001	Jan 19, 2005	Jan	CAHN
----	---------	--------	---------	-----	--------------	-----	------

AB		0.5MG	N021726	002	Jan 19, 2005	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB	+	1MG	N021726	003	Jan 19, 2005	Jan	CAHN
----	---	-----	---------	-----	--------------	-----	------

AB		2MG	N021726	004	Jan 19, 2005	Jan	CAHN
----	--	-----	---------	-----	--------------	-----	------

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS 12MG

N021775	001	May 20, 2008	Feb	CAHN
---------	-----	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Jan	CAHN
----	---	----------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL						
AMCINONIDE						
	+ FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002	Jan	CAHN
OINTMENT; TOPICAL						
AMCINONIDE						
AB	+ FOUGERA PHARMS	0.1%	A076096 001	Nov 19, 2002	Jan	CAHN
<u>AMIKACIN SULFATE</u>						
INJECTABLE; INJECTION						
AMIKACIN SULFATE						
	@ HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC
<u>AMINO ACIDS</u>						
INJECTABLE; INJECTION						
AMINO ACIDS						
	B BRAUN	15%(300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA
		15%(150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
NOVAMINE 15%						
	@ HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT
<u>AMINOCAPROIC ACID</u>						
INJECTABLE; INJECTION						
AMICAR						
	@ CLOVER PHARMS	250MG/ML	N015229 002		Mar	CAHN
SYRUP; ORAL						
AMICAR						
AA	+ CLOVER PHARMS	1.25GM/5ML	N015230 002		Mar	CAHN
TABLET; ORAL						
AMICAR						
AB	CLOVER PHARMS	500MG	N015197 001		Mar	CAHN
	+	1GM	N015197 002	Jun 24, 2004	Mar	CAHN
<u>AMIODARONE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
AMIODARONE HYDROCHLORIDE						
	@ BEDFORD	50MG/ML	A076018 001	Oct 15, 2002	Jun	DISC
	@ BEDFORD LABS	50MG/ML	A076299 001	Oct 24, 2002	Jun	DISC
	@ TEVA PARENTERAL	50MG/ML	A076163 001	Sep 05, 2003	Jan	DISC
TABLET; ORAL						
AMIODARONE HYDROCHLORIDE						
AB	MURTY PHARMS	200MG	A077069 001	Apr 08, 2005	May	CAHN
AB		400MG	A077069 002	Apr 08, 2005	May	CAHN
<u>AMITRIPTYLINE HYDROCHLORIDE</u>						
TABLET; ORAL						
AMITRIPTYLINE HYDROCHLORIDE						
AB	CARACO	10MG	A040816 002	Jun 27, 2008	Apr	NEWA
AB		50MG	A040816 003	Jun 27, 2008	Apr	NEWA
AB		75MG	A040816 004	Jun 27, 2008	Apr	NEWA
AB		100MG	A040816 005	Jun 27, 2008	Apr	NEWA
AB		150MG	A040816 006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC
+	EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
LIMBITROL					
@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
LIMBITROL DS					
@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	LEK PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
>D>	AB	LEK PHARMS DD	600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN
>A>	AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA	
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA	
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA	
>D>	AB	LEK PHARMS	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
>D>	AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN
>A>	AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
>A>	AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
	ADDERALL XR 15					
AB	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
	ADDERALL XR 20					
AB	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
	ADDERALL XR 25					
AB	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
	ADDERALL XR 30					
AB	+ SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
	ADDERALL XR 5					
AB	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG

CAPSULE, EXTENDED RELEASE; ORALDEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA

AMPHETAMINE SULFATETABLET; ORALAMPHETAMINE SULFATE

>A>	INDEPENDENCE PHARMS	5MG	A200166 001	Aug 09, 2012	Jul	NEWA
>A>	+	10MG	A200166 002	Aug 09, 2012	Jul	NEWA

AMPHOTERICIN BINJECTABLE, LIPID COMPLEX; INJECTIONAMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN

ANAGRELIDE HYDROCHLORIDECAPSULE; ORALAGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
	ANAGRELIDE HYDROCHLORIDE					
	@ SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
	@	EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC

ANASTROZOLETABLET; ORALANASTROZOLE

AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
AB	IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA

APROTINININJECTABLE; INJECTIONTRASYLOL

@	BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
---	----------------	--------------	-------------	--------------	-----	------

ARGATROBANINJECTABLE; INJECTIONACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
		ARGATROBAN					
AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA

ARMODAFINILTABLET; ORALARMODAFINIL

AB	MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
AB		150MG	A200043 002	Jun 01, 2012	May	NEWA
AB		250MG	A200043 003	Jun 01, 2012	May	NEWA
	NUVIGIL					
AB	CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
AB		150MG	N021875 003	Jun 15, 2007	May	CFTG

TABLET; ORAL

NUVIGIL

AB	+	CEPHALON	250MG	N021875 004	Jun 15, 2007	May	CFTG
----	---	----------	-------	-------------	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
----	--	----------------	---	-------------	--------------	-----	------

MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG
----	---	--------------	---	-------------	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

>A>		ORGANON SUB MERCK	EQ 5MG BASE	N022117 001	Aug 13, 2009	Jul	CAHN
>A>	+		EQ 10MG BASE	N022117 002	Aug 13, 2009	Jul	CAHN
>D>		ORGANON USA INC	EQ 5MG BASE	N022117 001	Aug 13, 2009	Jul	CAHN
>D>	+		EQ 10MG BASE	N022117 002	Aug 13, 2009	Jul	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN
----	--	-------------	-------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN
----	--	-------------	------------------	-------------	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@	ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010	Jun	DISC
@		25MG	A079017 002	Sep 17, 2010	Jun	DISC
@		40MG	A079017 003	Sep 17, 2010	Jun	DISC
@		60MG	A079017 004	Sep 17, 2010	Jun	DISC
@		80MG	A079017 005	Sep 17, 2010	Jun	DISC
@		100MG	A079017 006	Sep 17, 2010	Jun	DISC

STRATTERA

LILLY

+

		10MG	N021411 002	Nov 26, 2002	Jun	CTEC
		18MG	N021411 003	Nov 26, 2002	Jun	CTEC
		25MG	N021411 004	Nov 26, 2002	Jun	CTEC
		40MG	N021411 005	Nov 26, 2002	Jun	CTEC
		60MG	N021411 006	Nov 26, 2002	Jun	CTEC
		80MG	N021411 007	Feb 14, 2005	Jun	CTEC
		100MG	N021411 008	Feb 14, 2005	Jun	CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		APOTEX INC	EQ 10MG BASE	A090548 001	May 29, 2012	May	NEWA
AB			EQ 20MG BASE	A090548 002	May 29, 2012	May	NEWA
AB			EQ 40MG BASE	A090548 003	May 29, 2012	May	NEWA

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 80MG BASE	A090548 004	May 29, 2012	May	NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650 001	Jul 17, 2012	Jul NEWA
>A>	AB		EQ 20MG BASE	A091650 002	Jul 17, 2012	Jul NEWA
>A>	AB		EQ 40MG BASE	A091650 003	Jul 17, 2012	Jul NEWA
>A>	AB		EQ 80MG BASE	A202357 001	Jul 17, 2012	Jul NEWA
AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A091226 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A091226 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A091226 004	May 29, 2012	May	NEWA
AB	SANDOZ INC	EQ 10MG BASE	A077575 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A077575 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A077575 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

		50MG	N202276 001	Apr 27, 2012	Apr	NEWA
		100MG	N202276 002	Apr 27, 2012	Apr	NEWA
+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

		1MG	N202324 001	Jan 27, 2012	Jan	NEWA
+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002	Jun	CAHN
---	----------------	-----	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
AZELASTINE HYDROCHLORIDE							
AT	ALCON PHARMA	0.05%	A202305	001	May 31, 2012	May	NEWA
SPRAY, METERED; NASAL							
AZELASTINE HYDROCHLORIDE							
AB	SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423	001	May 23, 2012	May	NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL							
DYMISTA							
+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	May	NEWA

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL							
EDARBI							
	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN
+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL							
EDARBYCLOR							
	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN
+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Apr	CAHN

AZITHROMYCIN

INJECTABLE; INJECTION							
AZITHROMYCIN							
>D>	AP	PLIVA HRVATSKA D00	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Jul DISC
>A>		@	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Jul DISC
		@ TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006	Jun DISC
		@	EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006	Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC							
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE							
>A>	AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	Jul NEWA
>D>	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jul CTEC
>A>	AT	+	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jul CTEC

BACLOFEN

INJECTABLE; INTRATHECAL							
GABLOFEN							
	CNS THERAPS INC	1MG/ML	N022462	004	Jun 22, 2012	Jun	NEWA
TABLET; ORAL							
BACLOFEN							
AB	PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088	001	Oct 31, 2007	Feb	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL							
KEMSTRO							
	@ UCB INC	10MG	N021589	001	Oct 30, 2003	Jan	CAHN
	@	20MG	N021589	002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+	SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012	Feb	NEWA
---	--------------	-------	-------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar	NEWA
---	--------------------	-------------------	-------------	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@ NESHER PHARMS

100MG

A040795 001	Oct 31, 2007	Jun	DISC
-------------	--------------	-----	------

@

200MG

A040795 002	Oct 31, 2007	Jun	DISC
-------------	--------------	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

BT	+	VALEANT INTL	5%;EQ 1% BASE	N050756 002	Apr 20, 2007	Apr	CAHN
----	---	--------------	---------------	-------------	--------------	-----	------

AB			5%;EQ 1% BASE	N050756 001	Dec 21, 2000	Apr	CAHN
----	--	--	---------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		PERRIGO ISRAEL	5%;1.2%	A090979 001	Jun 26, 2012	Jun	NEWA
----	--	----------------	---------	-------------	--------------	-----	------

DUAC

AB	+	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002	Jun	CFTG
----	---	---------	---------	-------------	--------------	-----	------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984	Jan	CAHN
----	---	--------------	-------	-------------	--------------	-----	------

BENZAMYCIN PAK

+	VALEANT INTL	5%;3%	N050769 001	Nov 27, 2000	Jun	CAHN
---	--------------	-------	-------------	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012	Jan	NEWA
----	--	-------------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		APP PHARMS LLC	1MG/ML	A090233 001	Jul 28, 2009	May	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015 001		Feb	CAHN
----	---	------------------	--------	-------------	--	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ LANNETT HOLDINGS INC

0.5MG

A088877 001	Apr 11, 1985	Jan	DISC
-------------	--------------	-----	------

@

1MG

A088894 001	Apr 11, 1985	Jan	DISC
-------------	--------------	-----	------

@

2MG

A088895 001	Apr 11, 1985	Jan	DISC
-------------	--------------	-----	------

AA		PROSAM LABS	0.5MG	A040699 001	Feb 14, 2008	Feb	CMFD
----	--	-------------	-------	-------------	--------------	-----	------

AA			1MG	A040705 001	Feb 14, 2008	Feb	CMFD
----	--	--	-----	-------------	--------------	-----	------

AA			2MG	A040706 001	Feb 14, 2008	Feb	CMFD
----	--	--	-----	-------------	--------------	-----	------

AA	+	USL PHARMA	0.5MG	A040103 001	Dec 12, 1996	Jan	CRLD
----	---	------------	-------	-------------	--------------	-----	------

AA	+		1MG	A040103 002	Dec 12, 1996	Jan	CRLD
----	---	--	-----	-------------	--------------	-----	------

AA	+		2MG	A040103 003	Dec 12, 1996	Jan	CRLD
----	---	--	-----	-------------	--------------	-----	------

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ SCHERING

0.6MG/5ML

N014215 002

May DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB + FOUGERA PHARMS EQ 0.05% BASE

N019137 001 Jun 26, 1984 Jan CAHN

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB FOUGERA PHARMS EQ 0.05% BASE

A076215 001 Dec 09, 2003 Jan CAHN

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB + FOUGERA PHARMS EQ 0.05% BASE

A075276 001 May 13, 2003 Jan CAHN

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB FOUGERA PHARMS EQ 0.05% BASE

A077111 001 May 21, 2007 Jan CAHN

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB FOUGERA PHARMS EQ 0.05% BASE

A075373 001 Jun 22, 1999 Jan CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB FOUGERA PHARMS EQ 0.05% BASE;1%

A075502 001 Jun 05, 2001 Jan CAHN

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB FOUGERA PHARMS EQ 0.05% BASE;1%

A076516 001 Jun 16, 2005 Jan CAHN

LOTRISONE

AB + SCHERING CORP EQ 0.05% BASE;1%

N020010 001 Dec 08, 2000 Feb CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ STIEFEL EQ 0.12% BASE

N020934 001 Feb 28, 1999 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB TEVA WOMENS 5MG

N019982 002 Jul 31, 1992 Jan CAHN

AB + 10MG

N019982 001 Jul 31, 1992 Jan CAHN

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ MERCK SHARP DOHME 200MG

N202258 001 May 13, 2011 Mar CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL

N021602 001 May 13, 2003 Jan CDFR

BOSENTAN

TABLET; ORAL

TRACLEER

ACTELION PHARMS LTD	62.5MG	N021290 001	Nov 20, 2001	May	CAHN
+	125MG	N021290 002	Nov 20, 2001	May	CAHN

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT

@ ASTRAZENECA	0.16MG/INH	N020441 002	Jun 24, 1997	Jun	DISC
---------------	------------	-------------	--------------	-----	------

SUSPENSION; INHALATION

BUDESONIDE

>A> AN	WATSON LABS INC	0.25MG/2ML	A078404 001	Jul 31, 2012	Jul	NEWA
>A> AN		0.5MG/2ML	A078404 002	Jul 31, 2012	Jul	NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929 001	Jul 21, 2006	Jan	CDFR
+		0.16MG/INH;0.0045MG/INH	N021929 002	Jul 21, 2006	Jan	CDFR

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

>D>	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011	Jul	DISC
>A>		@	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011	Jul	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
+	EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
+	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
---	---------------------	-------	-------------	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
@ NESHER PHARMS	5MG	A075572 001	Feb 27, 2002	Jun	DISC
@	10MG	A075572 002	Feb 27, 2002	Jun	DISC
@	15MG	A075572 003	Feb 27, 2002	Jun	DISC
@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC

TABLET; ORAL						
BUSPIRONE HYDROCHLORIDE						
AB	PROSAM LABS	5MG	A075388 001	May 09, 2002	Feb	CMFD
	@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
	@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD
<u>BUTOCONAZOLE NITRATE</u>						
CREAM; VAGINAL						
BUTOCONAZOLE NITRATE						
	@ PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Apr	NEWA
<u>CAFFEINE CITRATE</u>						
SOLUTION; INTRAVENOUS						
CAFCIT						
AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
SOLUTION; ORAL						
CAFCIT						
AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
<u>CALCIPOTRIENE</u>						
CREAM; TOPICAL						
CALCIPOTRIENE						
AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
DOVONEX						
AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
SOLUTION; TOPICAL						
CALCIPOTRIENE						
AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
<u>CALCIUM ACETATE</u>						
CAPSULE; ORAL						
CALCIUM ACETATE						
AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
<u>CARBIDOPA; ENTACAPONE; LEVODOPA</u>						
TABLET; ORAL						
CARBIDOPA, LEVODOPA AND ENTACAPONE						
AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
STALEVO 100						
AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
STALEVO 150						
AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
<u>CARBIDOPA; LEVODOPA</u>						
TABLET, ORALLY DISINTEGRATING; ORAL						
PARCOPA						
AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA

PARAPLATIN

@ CORDEN PHARMA

@

@

50MG/VIAL

150MG/VIAL

450MG/VIAL

N019880 001 Mar 03, 1989 Feb CAHN

N019880 002 Mar 03, 1989 Feb CAHN

N019880 003 Mar 03, 1989 Feb CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

>A> CARFILZOMIB

>A> POWDER; INTRAVENOUS

>A> KYPROLIS

>A>	+ ONYX PHARMS	60MG/VIAL	N202714 001	Jul 20, 2012	Jul	NEWA
-----	---------------	-----------	-------------	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

@

EQ 250MG BASE

EQ 500MG BASE

A064156 001 Aug 28, 1997 Apr DISC

A064156 002 Aug 28, 1997 Apr DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

		EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
	@	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
	@	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
	@	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
AB		EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
AB		EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
AB		EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD	EQ 125MG BASE	A065092 001	Dec 22, 2003	Apr	DISC
@	EQ 187MG BASE	A065092 002	Dec 22, 2003	Apr	DISC
@	EQ 250MG BASE	A065092 003	Dec 22, 2003	Apr	DISC
@	EQ 375MG BASE	A065092 004	Dec 22, 2003	Apr	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999	Apr	DISC
--------------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

CEFADROXIL

@ RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999	Apr	DISC
-----------	-------------	-------------	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 2GM BASE/VIAL	N050779 003	Jan 13, 2012	May	NEWA
------------------	-------------	--------------	-----	------

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

200MG

N021222 001	Aug 29, 2001	Mar	CAHN
-------------	--------------	-----	------

+

400MG

N021222 002	Jul 21, 2008	Mar	CAHN
-------------	--------------	-----	------

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

>A> AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
--------	-------------	------------------	-------------	--------------	-----	------

>A> AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA
--------	--	------------------	-------------	--------------	-----	------

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG

N203195 001	Jun 01, 2012	Jun	NEWA
-------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
----	---	-------------------	------------------	-------------	--------------	-----	------

AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD
----	---	--	------------------	-------------	--------------	-----	------

>D> CEFOXITIN

>D> INJECTABLE; INJECTION

>D> CEFOXITIN

>D> AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN
--------	---------------------	------------------	-------------	--------------	-----	------

>D> AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN
--------	--	------------------	-------------	--------------	-----	------

>D> AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN
--------	--	-------------------	-------------	--------------	-----	------

>A> CEFOXITIN SODIUM

>A> INJECTABLE; INJECTION

>A> CEFOXITIN

>A> AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN
--------	---------------------	------------------	-------------	--------------	-----	------

>A> AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN
--------	--	------------------	-------------	--------------	-----	------

>A> AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN
--------	--	-------------------	-------------	--------------	-----	------

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006 Apr DISC

@

500MG

A065198 002 Dec 13, 2006 Apr DISC

CEFZIL

@ CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991 Feb CAHN

@

500MG

N050664 002 Dec 23, 1991 Feb CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA EQ 10MG BASE/ML

N050634 001 Apr 28, 1989 Apr CAHN

+ EQ 20MG BASE/ML

N050634 002 Apr 28, 1989 Apr CAHN

+ EQ 40MG BASE/ML

N050634 003 Apr 28, 1989 Apr CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ RANBAXY LABS LTD

EQ 125MG BASE

A065043 003 Feb 15, 2002 Apr DISC

@

EQ 250MG BASE

A065043 002 Feb 15, 2002 Apr DISC

@

EQ 500MG BASE

A065043 001 Feb 15, 2002 Apr DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
----	---	--------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZINACEF

AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
----	---	--------------	--------------------	-------------	--------------	-----	------

AP	+		EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
----	---	--	--------------------	-------------	--------------	-----	------

ZINACEF IN PLASTIC CONTAINER

+ COVIS PHARMA EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Apr CAHN

+ EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 Apr CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

>D>	@ LEX PHARMS	EQ 100MG BASE/ML	N050406 003		Jul	CAHN
>D>	@	EQ 125MG BASE/5ML	N050406 001		Jul	CAHN
>D>	@	EQ 250MG BASE/5ML	N050406 002		Jul	CAHN
>A>	@ SHIONOGI INC	EQ 100MG BASE/ML	N050406 003		Jul	CAHN
>A>	@	EQ 125MG BASE/5ML	N050406 001		Jul	CAHN
>A>	@	EQ 250MG BASE/5ML	N050406 002		Jul	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>D>	AA	RANBAXY	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
>A>		@ RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
	AA	SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
---	------------------	-----	-------------	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--------------------	---	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
+		0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
AB	GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

>A>	AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501 001	Jul 26, 2012	Jul	NEWA
	AP	MYLAN LLC	EQ 75MG BASE/ML	A201276 001	Jun 27, 2012	Jun	NEWA
		VISTIDE					
	AP	+ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996	Jun	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ HOSPIRA

EQ 300MG BASE/2ML

A074344 001 Jan 31, 1995 Jun DISC

@

EQ 300MG BASE/2ML

A074345 001 Jan 31, 1995 Jun DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@ TEVA PARENTERAL

200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006 Mar DISC

@

400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006 Jan DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

200MG/100ML

A077888 001 Mar 18, 2008 Jun DISC

@

400MG/200ML

A077888 002 Mar 18, 2008 Jun DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ PLIVA

EQ 100MG BASE

A076426 001 Jun 15, 2005 Jan DISC

@

EQ 250MG BASE

A076426 002 Jun 15, 2005 Jan DISC

@

EQ 500MG BASE

A076426 003 Jun 15, 2005 Jan DISC

@

EQ 750MG BASE

A076426 004 Jun 15, 2005 Jan DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
----	------------	----------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
----	------------	----------------	-------------	--------------	-----	------

AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
----	--	-----------------	-------------	--------------	-----	------

NIMBEX

AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
----	----------	----------------	-------------	--------------	-----	------

NIMBEX PRESERVATIVE FREE

AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
----	----------	----------------	-------------	--------------	-----	------

AP	+	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG
----	---	-----------------	-------------	--------------	-----	------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062 001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814 001	May 16, 2000	Mar	DISC

>A> CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

>A> FOR SOLUTION; ORAL

>A> PREPOPIK

>A>	+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC KET	N202535 001	Jul 16, 2012	Jul	NEWA
-----	---	-------------------	--	-------------	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>A>	AB	AUROBINDO	250MG	A065489 001	Jul 25, 2012	Jul	NEWA
>A>	AB		500MG	A065489 002	Jul 25, 2012	Jul	NEWA

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010	May	CRLD
----	---	-------------	-------------	-------------	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

	LUNDBECK LLC	5MG	N202067 001	Oct 21, 2011	Mar	CAHN
		10MG	N202067 002	Oct 21, 2011	Mar	CAHN
+		20MG	N202067 003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

>D>	AB	PERRIGO ISRAEL	0.05%	A077763 001	Mar 10, 2008	Jul	CTEC
>A>	AB1		0.05%	A077763 001	Mar 10, 2008	Jul	CTEC
>A>	AB2		0.05%	A201402 001	Aug 14, 2012	Jul	NEWA

OLUX

>D>	AB	+ STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	Jul	CTEC
>A>	AB1	+	0.05%	N021142 001	May 26, 2000	Jul	CTEC

OLUX E

>D>		+ STIEFEL LABS INC	0.05%	N022013 001	Jan 12, 2007	Jul	CFTG
>A>	AB2	+	0.05%	N022013 001	Jan 12, 2007	Jul	CFTG

CREAM; TOPICAL

CLOBETASOL PROPIONATE

		@ G AND W LABS INC	0.05%	A074139 001	Aug 03, 1994	Jun	CAHN
--	--	--------------------	-------	-------------	--------------	-----	------

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2		FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
-----	--	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB1	+	FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985	Jan	CAHN
-----	---	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+	FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB		TARO	0.05%	A200302 001	Jul 02, 2012	Jun	NEWA
----	--	------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A074407 001	Feb 23, 1996	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+	FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012	Jul	NEWA
-----	----	----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT		FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

		@ G AND W LABS INC	0.05%	A074331 001	Dec 15, 1995	Jun	CAHN
--	--	--------------------	-------	-------------	--------------	-----	------

TEMOVATE

AT	+	FOUGERA PHARMS	0.05%	N019966 001	Feb 22, 1990	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP		MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615 001	Oct 02, 1996	Feb	CAHN
AP	+		5 MG/10 ML (0.5 MG/ML)	N020615 002	Apr 27, 1999	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

		SHIONOGI INC	0.2MG	N022331 004	Sep 28, 2010	May	CMFD
--	--	--------------	-------	-------------	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB		APOTEX INC	EQ 75MG BASE	A076274 001	May 17, 2012	Apr	NEWA
----	--	------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540 001	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273 001	Jan 14, 2008	Mar	CMFD
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023 001	May 17, 2012	Apr	NEWA
AB	GATE PHARMS	EQ 300MG BASE	A091216 001	May 17, 2012	Apr	NEWA
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012	Apr	NEWA
AB		EQ 300MG BASE	A077665 002	May 17, 2012	Apr	NEWA
AB	ROXANE	EQ 75MG BASE	A078004 001	May 17, 2012	Apr	NEWA
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr	NEWA
AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr	NEWA
AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr	NEWA
>A> AB	WOCKHARDT LTD	EQ 75MG BASE	A202266 001	Aug 14, 2012	Jul	NEWA
PLAVIX						
AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar	CTEC
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@	LUNDBECK LLC	3.75MG	N017105 001		Mar	CAHN
@		7.5MG	N017105 002		Mar	CAHN
@		15MG	N017105 003		Mar	CAHN

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105 006		Mar	CAHN
AB		7.5MG	N017105 007		Mar	CAHN
AB	+	15MG	N017105 008		Mar	CAHN
TRANXENE SD						
@	LUNDBECK LLC	11.25MG	N017105 005		Mar	CAHN
@		22.5MG	N017105 004		Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ	12.5MG	N021590 004	May 30, 2007	Apr	CAHN
	25MG	N021590 001	Feb 10, 2004	Apr	CAHN
@	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+	100MG	N021590 002	Feb 10, 2004	Apr	CAHN
	150MG	N021590 005	Jul 09, 2010	Apr	CAHN
	200MG	N021590 006	Jul 09, 2010	Apr	CAHN
JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
	25MG	N021590 001	Feb 10, 2004	Jun	CAHN
@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+	100MG	N021590 002	Feb 10, 2004	Jun	CAHN
	150MG	N021590 005	Jul 09, 2010	Jun	CAHN
	200MG	N021590 006	Jul 09, 2010	Jun	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386 001	Jun 29, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984	May	CAHN
---	-------------	--------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	INNOPHARMA INC	0.25MG/VIAL	A202147 001	Jun 29, 2012	Jun	NEWA
----	----------------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@	KING PFIZER	0.8MG/INH	N018887 001	Dec 05, 1985	Jun	DISC
---	-------------	-----------	-------------	--------------	-----	------

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN
----	---	----------------------	-----------	-------------	--------------	-----	------

AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479 001	Feb 29, 1996	Jun	CAHN
----	---	------------------	-----------	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB	MYLAN	10MG	A073144 001	May 30, 1991	Jul	CRLD
-----	----	-------	------	-------------	--------------	-----	------

>A>	AB	+	MYLAN PHARMS INC	10MG	A073144 001	May 30, 1991	Jul	CRLD
-----	----	---	------------------	------	-------------	--------------	-----	------

	AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
--	----	-------------	-----	-------------	--------------	-----	------

	AB		10MG	A077209 001	Oct 04, 2005	Feb	CAHN
--	----	--	------	-------------	--------------	-----	------

FLEXERIL

>D>	AB	+	JANSSEN R AND D	10MG	N017821 002		Jul	DISC
-----	----	---	-----------------	------	-------------	--	-----	------

>D>	AB		JANSSEN RES AND DEV	5MG	N017821 001		Jul	DISC
-----	----	--	---------------------	-----	-------------	--	-----	------

>A>		@		5MG	N017821 001		Jul	DISC
-----	--	---	--	-----	-------------	--	-----	------

>A>		@		10MG	N017821 002		Jul	DISC
-----	--	---	--	------	-------------	--	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003		Apr	CRLD
----	---	-----------------	------------	-------------	--	-----	------

AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Apr	CRLD
----	---	--	----------	-------------	--------------	-----	------

AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Apr	CRLD
----	---	--	----------	-------------	--------------	-----	------

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1		WATSON LABS INC	25MG	A065044 002	Dec 20, 2000	May	CAHN
-----	--	-----------------	------	-------------	--------------	-----	------

AB1			100MG	A065044 001	Dec 20, 2000	May	CAHN
-----	--	--	-------	-------------	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP		ONCO THERAPIES LTD	100MG/ML	A201784 001	Jan 30, 2012	Jan	NEWA
----	--	--------------------	----------	-------------	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		Mar	CAHN
----	---	--------------	------------	-------------	--	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

>D>		@ ACTAVIS TOTOWA	25MG	A076686 001	Oct 24, 2005	Jul	CAHN
>D>		@	50MG	A076686 002	Oct 24, 2005	Jul	CAHN
>D>		@	100MG	A076686 003	Oct 24, 2005	Jul	CAHN
>A>		@ MIKAH PHARMA	25MG	A076686 001	Oct 24, 2005	Jul	CAHN
>A>		@	50MG	A076686 002	Oct 24, 2005	Jul	CAHN
>A>		@	100MG	A076686 003	Oct 24, 2005	Jul	CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

>A>		DAPIPRAZOLE HYDROCHLORIDE					
>A>		@ FERA PHARMS	0.5%	N019849 001	Dec 31, 1990	Jul	CTNA
>D>		REV-EYES					
>D>		@ FERA PHARMS	0.5%	N019849 001	Dec 31, 1990	Jul	CTNA

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011	Feb	CAHN
---	---------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

PREZISTA

	JANSSEN PRODS	EQ 75MG BASE	N021976 004	Dec 18, 2008	Feb	CAHN
		EQ 150MG BASE	N021976 005	Dec 18, 2008	Feb	CAHN
	@	EQ 300MG BASE	N021976 001	Jun 23, 2006	Feb	CAHN
		EQ 400MG BASE	N021976 003	Oct 21, 2008	Feb	CAHN
+		EQ 600MG BASE	N021976 002	Feb 25, 2008	Feb	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

>D>		DECLOMYCIN					
>D>	AB	COREPHARMA	150MG	N050261 002		Jul	DISC
>A>		@	150MG	N050261 002		Jul	DISC
>D>	AB	+	300MG	N050261 003		Jul	DISC
>A>		@	300MG	N050261 003		Jul	DISC

DEMECLOCYCLINE HYDROCHLORIDE

>D>	AB	AMNEAL PHARM	300MG	A065425 002	Feb 27, 2008	Jul	CRLD
>A>	AB	+	300MG	A065425 002	Feb 27, 2008	Jul	CRLD

DESFLURANE

LIQUID; INHALATION

SUPRANE

>A>	+	BAXTER HLTHCARE	99.9%	N020118 001	Sep 18, 1992	Jul	CAHN
>D>	+	BAXTER HLTHCARE CORP	99.9%	N020118 001	Sep 18, 1992	Jul	CAHN

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB		BELCHER PHARMS	5MG	A078355 001	Apr 19, 2012	Apr	NEWA
----	--	----------------	-----	-------------	--------------	-----	------

TABLET; ORAL									
DESLOMATADINE									
AB	MYLAN PHARMS INC	5MG		A078351 001	Feb 10, 2012	Jan	NEWA		
<u>DESMOPRESSIN ACETATE</u>									
SOLUTION; NASAL									
DDAVP									
AB	+ SANOFI AVENTIS US	0.01%		N017922 001		Mar	CFTG		
DESMOPRESSIN ACETATE									
AB	SUN PHARM INDS	0.01%		A077212 001	Apr 12, 2012	Mar	NEWA		
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>									
TABLET; ORAL-28									
MIRCETTE									
AB	+ TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG		N020713 001	Apr 22, 1998	Jun	CAHN		
VIORELE									
AB	GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG		A091346 001	Apr 02, 2012	Mar	NEWA		
<u>DESONIDE</u>									
LOTION; TOPICAL									
DESONIDE									
AB	FOUGERA PHARMS	0.05%		A075860 001	Mar 19, 2002	Jan	CAHN		
OINTMENT; TOPICAL									
DESONIDE									
AB	FOUGERA PHARMS	0.05%		A075751 001	Mar 12, 2001	Jan	CAHN		
<u>DESOXIMETASONE</u>									
CREAM; TOPICAL									
DESOXIMETASONE									
AB	FOUGERA PHARMS	0.25%		A078369 001	Jun 29, 2010	Jan	CAHN		
TOPICORT									
	+ TARO	0.05%		A073210 001	Nov 30, 1990	Apr	CTNA		
	+	0.25%		A073193 001	Nov 30, 1990	Apr	CTNA		
	@ TARO PHARMS NORTH	0.25%		N017856 001		Apr	DISC		
TOPICORT LP									
	@ TARO PHARMS NORTH	0.05%		N018309 001		Apr	DISC		
GEL; TOPICAL									
TOPICORT									
AB	+ TARO	0.05%		A074904 001	Jul 14, 1998	Apr	CTNA		
	@ TARO PHARMS NORTH	0.05%		N018586 001	Mar 29, 1982	Apr	DISC		
OINTMENT; TOPICAL									
DESOXIMETASONE									
AB	+ TARO	0.25%		A074286 001	Jun 07, 1996	Mar	CRLD		
TOPICORT									
	+ TARO	0.25%		A074286 001	Jun 07, 1996	Apr	CTNA		
	@ TARO PHARMS NORTH	0.25%		N018763 001	Sep 30, 1983	Mar	DISC		
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>									
INJECTABLE; INJECTION									
DEXAMETHASONE SODIUM PHOSPHATE									
AP	+ APP PHARMS LLC	EQ 10MG PHOSPHATE/ML		A040572 001	Apr 22, 2005	Feb	CRLD		
<u>DEXRAZOXANE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
TOTECT									
	+ APRICUS PHARMS	EQ 500MG BASE/VIAL		N022025 001	Sep 06, 2007	Jun	CAHN		

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687 001	Jun 28, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

>D>	@ BAXTER HLTHCARE	5MG/ML	A071309 001	Jul 17, 1987	Jul	CAHN
>D>	@	5MG/ML	A070313 001	Dec 16, 1985	Jul	CAHN
>D>	@	5MG/ML	A070311 001	Dec 16, 1985	Jul	CAHN
>D>	@	5MG/ML	A071308 001	Jul 17, 1987	Jul	CAHN
>D>	@	5MG/ML	A070312 001	Dec 16, 1985	Jul	CAHN
>D>	@	5MG/ML	A071310 001	Jul 17, 1987	Jul	CAHN
>A>	@ HIKMA MAPLE	5MG/ML	A070312 001	Dec 16, 1985	Jul	CAHN
>A>	@	5MG/ML	A070311 001	Dec 16, 1985	Jul	CAHN
>A>	@	5MG/ML	A070313 001	Dec 16, 1985	Jul	CAHN
>A>	@	5MG/ML	A071308 001	Jul 17, 1987	Jul	CAHN
>A>	@	5MG/ML	A071309 001	Jul 17, 1987	Jul	CAHN
>A>	@	5MG/ML	A071310 001	Jul 17, 1987	Jul	CAHN
	@ HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987	Apr	DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+	DEPOMED INC	25MG	N022202 001	Jun 16, 2009	Jun	CAHN
---	-------------	------	-------------	--------------	-----	------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	GD SEARLE LLC	50MG;0.2MG	N020607 001	Dec 24, 1997	Jun	CFTG
AB	+	75MG;0.2MG	N020607 002	Dec 24, 1997	Jun	CFTG
	DICLOFENAC SODIUM AND MISOPROSTOL					
AB	WATSON LABS INC	50MG;0.2MG	A201089 001	Jul 09, 2012	Jun	NEWA
AB		75MG;0.2MG	A201089 002	Jul 09, 2012	Jun	NEWA

DIDANOSINE

TABLET, CHEWABLE; ORAL

DIDANOSINE

>A>	AUROBINDO	100MG	A077275 001	Aug 14, 2012	Jul	NEWA
>A>		150MG	A077275 002	Aug 14, 2012	Jul	NEWA
>A>		200MG	A077275 003	Aug 14, 2012	Jul	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187 001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		EMCURE PHARMS USA	500MG	A202845 001	Mar 08, 2012	Feb	NEWA
AB	+	TEVA	500MG	A073673 001	Jul 31, 1992	Feb	CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

>D>	AP	BAXTER HLTHCARE	0.25MG/ML	A083391 001		Jul	CAHN
>A>	AP	HIKMA MAPLE	0.25MG/ML	A083391 001		Jul	CAHN
		@ HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

>D>		@ ACTAVIS TOTOWA	0.125MG	A040282 001	Dec 23, 1999	Jul	CAHN
>D>		@	0.25MG	A040282 002	Dec 23, 1999	Jul	CAHN
>A>		@ MYLAN PHARMS INC	0.125MG	A040282 001	Dec 23, 1999	Jul	CAHN
>A>		@	0.25MG	A040282 002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	5MG/ML	A078538 001	Dec 17, 2008	Jul	CAHN
>A>	AP	HIKMA FARMACEUTICA	5MG/ML	A202651 001	Aug 09, 2012	Jul	NEWA
>A>	AP	HIKMA MAPLE	5MG/ML	A078538 001	Dec 17, 2008	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Jan	DISC

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

>D>	+	CONTROLLED THERAP	10MG	N020411 001	Mar 30, 1995	Jul	CAHN
>A>	+	FERRING CONTROLLED	10MG	N020411 001	Mar 30, 1995	Jul	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

		@ MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC
--	--	---------------	---------	-------------	--	-----	------

BENADRYL PRESERVATIVE FREE

		@ MCNEIL CONS	50MG/ML	N009486 001		Mar	DISC
--	--	---------------	---------	-------------	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AP	+	BAXTER HLTHCARE	50MG/ML	A080817 002	Jul	CAHN
>D>			@	50MG/ML	A083183 001	Jul	CAHN
	AP	+		50MG/ML	A080817 002	Apr	CRLD
>A>	AP	+	HIKMA MAPLE	50MG/ML	A080817 002	Jul	CAHN
>A>			@	50MG/ML	A083183 001	Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D>	AP	BAXTER HLTHCARE	5MG/ML	A074521 001	Oct 18, 1996	Jul	CAHN
>A>	AP	HIKMA MAPLE	5MG/ML	A074521 001	Oct 18, 1996	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
----	--	-------------	------	-------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@ NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
-----------------	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
	TAXOTERE					
AP +	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP +		80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012	Jul	NEWA
>A>	AB		10MG	A201634 002	Jun 13, 2012	Jul	NEWA
	AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
	AB		10MG	A200292 002	May 31, 2011	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+ MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
---------------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@	EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@	EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@	EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+ FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
------------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
>A>	AP	SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012	Jul NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

MONODOX

>A>	AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul CAHN
>A>	AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul CAHN
>A>	AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul CAHN
>D>	AB	WATSON PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul CAHN
>D>	AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul CAHN
>D>	AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul CAHN

TABLET; ORAL

DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
	@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
	@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

>D>	@	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul CAHN
>D>	@		EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul CAHN
>A>	@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul CAHN
>A>	@		EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul CAHN

DOXYCYCLINE HYCLATE

>D>	@	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul CAHN
>D>	@		EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul CAHN
>A>	@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul CAHN
>A>	@		EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
----	-------------	--------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan CTEC
----	---	--------------	---------------	-------------	--------------	----------

DOXYCYCLINE HYCLATE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA
----	------------------	---------------	-------------	--------------	-----	------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

	BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	Apr	CAIN
---	---------------------	--------------------------	---------	-----	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb	DISC
@		2.5MG	A075496	001	Aug 22, 2000	Jan	DISC
@		5MG	A075621	002	Aug 22, 2000	Feb	DISC
@		5MG	A075496	002	Aug 22, 2000	Jan	DISC
@		10MG	A075621	003	Aug 22, 2000	Feb	DISC
@		10MG	A075459	001	Aug 22, 2000	Jan	DISC
@		20MG	A075621	004	Aug 22, 2000	Feb	DISC
@		20MG	A075459	002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
@		10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC

ENFLURANE

LIQUID; INHALATION

ETHRANE

>A>	AN	+	BAXTER HLTHCARE	99.9%	N017087	001	Jul	CAHN
>D>	AN	+	BAXTER HLTHCARE CORP	99.9%	N017087	001	Jul	CAHN

ENTACAPONE

TABLET; ORAL

COMTAN

>D>		+	ORION PHARMA	200MG	N020796	001	Oct 19, 1999	Jul	CFTG
>A>	AB	+		200MG	N020796	001	Oct 19, 1999	Jul	CFTG
		+		200MG	N020796	001	Oct 19, 1999	May	CAHN
>A>			ENTACAPONE						
>A>	AB		SUN PHARMA GLOBAL	200MG	A090690	001	Jul 16, 2012	Jul	NEWA
>A>	AB		WOCKHARDT LTD	200MG	A078941	001	Aug 16, 2012	Jul	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT			LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
----	--	--	----------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALIN

BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN

INJECTABLE; IM-SC

TWINJECT 0.15

BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800 002	May 28, 2004	Mar	CAHN
----	---	------------	---------------------	-------------	--------------	-----	------

TWINJECT 0.3

BX	+	COREPHARMA	EQ 0.3MG /DELIVERY	N020800 001	May 30, 2003	Mar	CAHN
----	---	------------	--------------------	-------------	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048 001		May	CRLD
----	---	-----------	--------------	-------------	--	-----	------

XYLOCAINE DENTAL WITH EPINEPHRINE

@ DENTSPLY PHARM 0.01MG/ML;2%

N021381 001	May	DISC
-------------	-----	------

@ 0.02MG/ML;2%

N021381 002	May	DISC
-------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	50MG/25ML (2MG/ML)	A065361 001	Oct 22, 2007	Mar	CAHN
----	--	-----------	--------------------	-------------	--------------	-----	------

AP			200MG/100ML (2MG/ML)	A065361 002	Oct 22, 2007	Mar	CAHN
----	--	--	----------------------	-------------	--------------	-----	------

AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	CAHN
----	--	----------------------	--------------------	-------------	--------------	-----	------

AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	CAHN
----	--	--	----------------------	-------------	--------------	-----	------

AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012	Mar	NEWA
----	--	--------------------	--------------------	-------------	--------------	-----	------

AP			200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012	Mar	NEWA
----	--	--	----------------------	-------------	--------------	-----	------

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

ACTELION PHARMS LTD EQ 0.5MG BASE/VIAL

N022260 002	Jun 28, 2012	Jun	NEWA
-------------	--------------	-----	------

+ EQ 1.5MG BASE/VIAL

N022260 001	Jun 27, 2008	May	CAHN
-------------	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB		WARNER CHILCOTT LLC	250MG	A062338 001		Jun	CAHN
----	--	---------------------	-------	-------------	--	-----	------

GEL; TOPICAL

E-GLADES

>D>	AT	COREPHARMA	2%	A065009 001	Mar 18, 2002	Jul	DISC
-----	----	------------	----	-------------	--------------	-----	------

>A>		@	2%	A065009 001	Mar 18, 2002	Jul	DISC
-----	--	---	----	-------------	--------------	-----	------

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYCETTE

@ JOHNSON AND JOHNSON 2%

N050594 001	Feb 15, 1985	Apr	CAHN
-------------	--------------	-----	------

ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A065320 001	Jul 25, 2006	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227 001	Mar 14, 2012	Feb	NEWA
----	--	---------------	-----------------	-------------	--------------	-----	------

AA		AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062 001	Apr 02, 2012	Mar	NEWA
----	--	----------------------	-----------------	-------------	--------------	-----	------

AA		HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221 001	Jun 12, 2012	May	NEWA
----	--	---------------------	-----------------	-------------	--------------	-----	------

AA		TARO	EQ 5MG BASE/5ML	A079121 001	May 03, 2012	Apr	NEWA
----	--	------	-----------------	-------------	--------------	-----	------

SOLUTION; ORAL						
LEXAPRO						
AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365 001	Nov 27, 2002	Feb CFTG
TABLET; ORAL						
ESCITALOPRAM OXALATE						
AB		IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765 001	Mar 14, 2012	Feb NEWA
AB			EQ 10MG BASE	A076765 002	Mar 14, 2012	Feb NEWA
AB			EQ 20MG BASE	A076765 003	Mar 14, 2012	Feb NEWA
LEXAPRO						
AB		FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002	Feb CFTG
AB			EQ 10MG BASE	N021323 002	Aug 14, 2002	Feb CFTG
AB	+		EQ 20MG BASE	N021323 003	Aug 14, 2002	Feb CFTG
<u>ESMOLOL HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
BREVIBLOC						
AP	+	BAXTER HLTHCARE	10MG/ML	N019386 006	Feb 25, 2003	Jun CAHN
		@	10MG/ML	N019386 003	Aug 15, 1988	Jun CAHN
		@	20MG/ML	N019386 007	May 28, 2003	Jun CAHN
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003	Jun CAHN
BREVIBLOC IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001	Jun CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>						
FOR SUSPENSION, DELAYED RELEASE; ORAL						
NEXIUM						
		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011	Jun NEWA
			EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011	Jun NEWA
<u>ESTRADIOL</u>						
CREAM; VAGINAL						
ESTRACE						
	+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984	Jun CAHN
GEL, METERED; TRANSDERMAL						
ELESTRIN						
	+	JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Jun CAHN
<u>ESTRADIOL ACETATE</u>						
INSERT, EXTENDED RELEASE; VAGINAL						
FEMRING						
		WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003	May CAHN
	+		EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003	May CAHN
TABLET; ORAL						
FEMTRACE						
		WARNER CHILCOTT LLC	0.45MG	N021633 001	Aug 20, 2004	Jun CAHN
			0.9MG	N021633 002	Aug 20, 2004	Jun CAHN
	+		1.8MG	N021633 003	Aug 20, 2004	Jun CAHN
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>						
TABLET; ORAL						
ESTRADIOL AND NORETHINDRONE ACETATE						
AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012	Feb NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

	TEVA BRANDED PHARM	0.3MG	N020992 001	Jun 21, 2002	Jun	CAHN
		0.45MG	N020992 005	Feb 05, 2004	Jun	CAHN
		0.625MG	N020992 002	Mar 24, 1999	Jun	CAHN
		0.9MG	N020992 003	Mar 24, 1999	Jun	CAHN
+		1.25MG	N020992 004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

		+	WATSON LABS	0.02MG;0.09MG	A079218 001	Jun 06, 2011	May	CRLD
			LOSEASONIQUE					
	AB		TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008	Jun	CAHN
			LYBREL					
			@ WYETH PHARMS INC	0.02MG;0.09MG	N021864 001	May 22, 2007	May	DISC
			PREVEN EMERGENCY CONTRACEPTIVE KIT					
			@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946 001	Sep 01, 1998	Jun	CAHN
			SEASONALE					
>D>	AB	+	DURAMED RES	0.03MG;0.15MG	N021544 001	Sep 05, 2003	Jul	CAHN
>A>	AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544 001	Sep 05, 2003	Jul	CAHN
			SEASONIQUE					
	AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006	Jun	CAHN
			TABLET; ORAL-21					
			NORDETTE-21					
			@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668 001	May 10, 1982	Jun	CAHN
			TABLET; ORAL-28					
			FALMINA					
	AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721 001	Mar 28, 2012	Mar	NEWA
			MARLISSA					
	AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452 001	Feb 29, 2012	Feb	NEWA
			MYZILRA					
	AB		VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502 001	Nov 23, 2011	May	CDFR
			NORDETTE-28					
	AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782 001	Jul 21, 1982	Jun	CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+	JANSSEN PHARMS	0.75MG;6MG	N021180 001	Nov 20, 2001	Jun	CPOT
---	----------------	------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB		GLENMARK GENERICS	0.035MG;1MG	A091634 001	Jan 19, 2012	Jan	NEWA
		ALYACEN 7/7/7					
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636 001	Jan 19, 2012	Jan	NEWA
		OVCON-35					
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716 001		Jun	CAHN
		OVCON-50					
	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576 001		Jun	CAHN
		WERA					
AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204 001	Mar 27, 2012	Mar	NEWA

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490 001	Nov 14, 2003	Jun	CAHN
----	---	---------------------	---------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065 001	Jan 14, 2005	Jun	CAHN
AB	+		0.005MG;1MG	N021065 002	Oct 15, 1999	Jun	CAHN

LO LOESTRIN FE

	+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN
--	---	---------------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL-21

ESTROSTEP 21

	@	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
--	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN 21 1.5/30

AB		WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875 001		Jun	CAHN
----	--	---------------------	--------------	-------------	--	-----	------

LOESTRIN 21 1/20

AB		WARNER CHILCOTT LLC	0.02MG;1MG	N017876 001		Jun	CAHN
----	--	---------------------	------------	-------------	--	-----	------

TABLET; ORAL-28

ESTROSTEP FE

AB	+	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
----	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN FE 1.5/30

AB	+	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN
----	---	---------------------	--------------	-------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

AB		NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
----	--	-----------------	----------------	-------------	--------------	-----	------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
----	--	-------------------	----------------	-------------	--------------	-----	------

AB		LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
----	--	--------------	---	-------------	--------------	-----	------

TRI-LINYAH

AB		NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
----	--	-----------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB		NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	--	-----------------	--------------	-------------	--------------	-----	------

ETODOLAC

TABLET; ORAL

ETODOLAC

AB		PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	--	-------------	-------	-------------	--------------	-----	------

AB			500MG	A074819 002	Apr 28, 1998	Feb	CMFD
----	--	--	-------	-------------	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP		MYLAN INSTITUTIONAL	2MG/ML	A091297 001	Jun 20, 2012	Jun	NEWA
----	--	---------------------	--------	-------------	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

	@	CORDEN PHARMA	50MG	N019557 001	Dec 30, 1986	Feb	CAHN
--	---	---------------	------	-------------	--------------	-----	------

CAPSULE; ORAL									
VEPESID									
	@ CORDEN PHARMA	100MG				N019557	002	Dec 30, 1986	Feb CAHN
INJECTABLE; INJECTION									
ETOPOSID									
AP	+ APP PHARMS LLC	20MG/ML				A074983	001	Sep 30, 1998	Mar CRLD
AP	BEDFORD	20MG/ML				A074290	001	Jul 17, 1995	Mar CRLD
VEPESID									
	@ CORDEN PHARMA	20MG/ML				N018768	001	Nov 10, 1983	Feb CAHN
<u>ETRAVIRINE</u>									
TABLET; ORAL									
INTELENCE									
	JANSSEN R AND D	25MG				N022187	003	Mar 26, 2012	Mar NEWA
		100MG				N022187	001	Jan 18, 2008	Feb CAHN
	+	200MG				N022187	002	Dec 22, 2010	Feb CAHN
<u>EVEROLIMUS</u>									
TABLET; ORAL									
AFINITOR									
	NOVARTIS	7.5MG				N022334	004	Mar 30, 2012	Apr NEWA
<u>EXENATIDE SYNTHETIC</u>									
FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS									
BYDUREON									
	+ AMYLIN	2MG/VIAL				N022200	001	Jan 27, 2012	Jan NEWA
<u>EZETIMIBE</u>									
TABLET; ORAL									
ZETIA									
	+ MSD INTL GMBH	10MG				N021445	001	Oct 25, 2002	Feb CAHN
	+ MSP SINGAPORE	10MG				N021445	001	Oct 25, 2002	Jan CAHN
<u>EZETIMIBE; SIMVASTATIN</u>									
TABLET; ORAL									
VYTORIN									
	MSD INTL	10MG;10MG				N021687	001	Jul 23, 2004	Jan CAHN
		10MG;20MG				N021687	002	Jul 23, 2004	Jan CAHN
		10MG;40MG				N021687	003	Jul 23, 2004	Jan CAHN
	+	10MG;80MG				N021687	004	Jul 23, 2004	Jan CAHN
<u>EZOGABINE</u>									
TABLET; ORAL									
POTIGA									
	GLAXOSMITHKLINE	50MG				N022345	001	Jun 10, 2011	May CAHN
		200MG				N022345	002	Jun 10, 2011	May CAHN
		300MG				N022345	003	Jun 10, 2011	May CAHN
	+	400MG				N022345	004	Jun 10, 2011	May CAHN
<u>FAMCICLOVIR</u>									
TABLET; ORAL									
FAMCICLOVIR									
AB	MACLEODS PHARMS LTD	125MG				A201022	001	Jan 12, 2012	Jan NEWA
AB		250MG				A201022	002	Jan 12, 2012	Jan NEWA
AB		500MG				A201022	003	Jan 12, 2012	Jan NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D>	AP	+	BAXTER HLTHCARE	10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN
>D>	AP	+		10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN
>A>	AP	+	HIKMA MAPLE	10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN
>A>	AP	+		10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN

FAMOTIDINE PRESERVATIVE FREE

>D>	AP	+	BAXTER HLTHCARE	10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN
>D>	AP	+		10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
>A>	AP	+	HIKMA MAPLE	10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
>A>	AP	+		10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN

TABLET; ORAL

PEPCID

AB			MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB	+			40MG	N019462 002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	@	UCB INC	20MG	N021712 001	Sep 24, 2004	Jan	CAHN
	@		40MG	N021712 002	Sep 24, 2004	Jan	CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

			TAKEDA PHARMS USA	40MG	N021856 001	Feb 13, 2009	Apr	CAHN
	+			80MG	N021856 002	Feb 13, 2009	Apr	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>A>	AB		WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012	Jul	NEWA
>A>	AB			5MG	A091484 002	Aug 15, 2012	Jul	NEWA
>A>	AB			10MG	A091484 003	Aug 15, 2012	Jul	NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB			LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
AB	+			130MG	N021695 003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

AB			DR REDDYS LABS SA	43MG	A090859 001	Mar 01, 2012	Feb	NEWA
AB				130MG	A090859 002	Mar 01, 2012	Feb	NEWA

TABLET; ORAL

FENOFIBRATE

AB			IMPAX LABS	160MG	A076509 002	Mar 26, 2008	May	CRLD
AB	+			160MG	A076509 002	Mar 26, 2008	Mar	CRLD
AB			TEVA	54MG	A076433 001	May 13, 2005	May	CMFD
	@			54MG	A076433 001	May 13, 2005	Mar	DISC
AB	+			160MG	A076433 002	May 13, 2005	May	CMFD
	@			160MG	A076433 002	May 13, 2005	Mar	DISC
AB			VALEANT INTL	48MG	A090715 001	Apr 05, 2012	Mar	NEWA
AB				145MG	A090715 002	Apr 05, 2012	Mar	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100							
AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jun	CAHN
FENTANYL-25							
AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jun	CAHN
FENTANYL-50							
AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jun	CAHN
FENTANYL-75							
AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jun	CAHN

SPRAY; SUBLINGUAL
SUBSYS

INSYS THERAP		0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA
		0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATESPRAY, METERED; NASAL
LAZANDA

ARCHIMEDES		EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE							
AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

@ AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996	Jun	DISC
-------------------	-------------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

>D>	+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG
>A>	AB	+	30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG
		FEXOFENADINE HYDROCHLORIDE						
>A>	AB	ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Jun	CPOT
+		10-50ML (13.5-51CMI/ML)	N202008	003	Apr 06, 2012	Apr	NEWA

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA
+		10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL

FLUCONAZOLE

>D>	AB	AMNEAL PHARM	50MG	A078423 001	Mar 07, 2011	Jul	CAHN
>D>	AB		100MG	A078423 002	Mar 07, 2011	Jul	CAHN
>D>	AB		150MG	A078423 003	Mar 07, 2011	Jul	CAHN
>D>	AB		200MG	A078423 004	Mar 07, 2011	Jul	CAHN
>A>	AB	HARRIS PHARM	50MG	A078423 001	Mar 07, 2011	Jul	CAHN
>A>	AB		100MG	A078423 002	Mar 07, 2011	Jul	CAHN
>A>	AB		150MG	A078423 003	Mar 07, 2011	Jul	CAHN
>A>	AB		200MG	A078423 004	Mar 07, 2011	Jul	CAHN
		@ PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
		@	100MG	A076424 002	Jul 29, 2004	Feb	DISC
		@	150MG	A076424 003	Jul 29, 2004	Feb	DISC
		@	200MG	A076424 004	Jul 29, 2004	Feb	DISC
		@ RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
		@	100MG	A076386 002	Jul 29, 2004	Apr	DISC
		@	150MG	A076386 003	Jul 29, 2004	Apr	DISC
		@	200MG	A076386 004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@	GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar	DISC
---	--------------	-----------	-------------	--------------	-----	------

FLUDARABINE PHOSPHATE

AP	+	HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar	CRLD
----	---	---------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OFORTA

@	SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	May	DISC
---	-------------------	------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

>D>	AP	BAXTER HLTHCARE	0.5MG/5ML (0.1MG/ML)	A076787 002	Oct 12, 2004	Jul	CAHN
>D>	AP		1MG/10ML (0.1MG/ML)	A076787 001	Oct 12, 2004	Jul	CAHN
>A>	AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787 002	Oct 12, 2004	Jul	CAHN
>A>	AP		1MG/10ML (0.1MG/ML)	A076787 001	Oct 12, 2004	Jul	CAHN
		@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Jan	DISC
		@	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Jan	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

>D>	+	ACTON PHARMS	EQ 78MCG BASE/INH	N021247 001	Jan 27, 2006	Jul	CPOT
-----	---	--------------	-------------------	-------------	--------------	-----	------

AEROSOL, METERED; INHALATION

AEROSPAN HFA

>A>	+	ACTON PHARMS	EQ 78MG BASE/INH	N021247 001	Jan 27, 2006	Jul	CPOT
-----	---	--------------	------------------	-------------	--------------	-----	------

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	--	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2		FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
		@ G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995	May	CAHN

OINTMENT; TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

CARAC

>D>	+	SANOFI AVENTIS US	0.5%	N020985 001	Oct 27, 2000	Jul	CAHN
>A>	+	VALEANT INTL	0.5%	N020985 001	Oct 27, 2000	Jul	CAHN

FLUOROPLEX

+	AQUA PHARMS	1%	N016988 001			Jan	CAHN
---	-------------	----	-------------	--	--	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

>A>	AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668 001	Jul 17, 2012	Jul	NEWA
>A>	AP		1GM/20ML (50MG/ML)	A202668 002	Jul 17, 2012	Jul	NEWA
>A>	AP		2.5GM/50ML (50MG/ML)	A202669 001	Jul 17, 2012	Jul	NEWA
>A>	AP		5GM/100ML (50MG/ML)	A202669 002	Jul 17, 2012	Jul	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

AB1		ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
AB1			EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
AB	+		EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
		@	EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN

SARAFEM

AB2		ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
AB2	+		EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

		WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
			EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
	+		EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
AB			EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
AB			EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
AB			EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA

CAPSULE; ORAL

SYMBYAX

AB	LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>A>	AQUA PHARMS	0.025%	N012806 003		Jul	CAHN
>A>		0.05%	N012806 002		Jul	CAHN
>D>	WATSON PHARMS	0.025%	N012806 003		Jul	CAHN
>D>		0.05%	N012806 002		Jul	CAHN
		0.05%	N012806 002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

>A>	+ AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
>D>	+ WATSON LABS	0.05%	N013790 001		Jul	CAHN

OINTMENT; TOPICAL

CORDRAN

>A>	@ AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
>A>	@	0.05%	N012806 001		Jul	CAHN
>D>	@ WATSON PHARMS	0.025%	N012806 004		Jul	CAHN
>D>	@	0.05%	N012806 001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+ IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
AB	SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+ FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
	@ NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA

LESCOL

AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
+	150MG	N022033 002	Feb 28, 2008	Jun	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
@	20MG	A076580 002	Apr 23, 2004	Apr	DISC
@	40MG	A076580 003	Apr 23, 2004	Apr	DISC

MONOPRIL

@ BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
@	20MG	N019915 003	May 16, 1991	Mar	DISC
@	40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D>	AP	BAXTER HLTHCARE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
>A>	AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
		@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

>D>							
>D>	+	EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC
>A>		@	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC
-----------	---------	-------------	--------------	-----	------

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
@	500MG	A076457 002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
	@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
	@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
	@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
	@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

GRISOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
----	-----------------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

GRIFULVIN V

>D>	@ ORTHO JANSSEN	125MG	A062279 001		Jul	CAHN
>D>	@	250MG	A062279 002		Jul	CAHN
>D>	+	500MG	A062279 003		Jul	CAHN
>A>	@ VALEANT INTL	125MG	A062279 001		Jul	CAHN
>A>	@	250MG	A062279 002		Jul	CAHN
>A>	+	500MG	A062279 003		Jul	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
		@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
>A>	AP	+	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
--	--	-------------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
--	--	-------------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD
>A>	AP	+	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
--	--	-------------------	-------------------	-------------	--------------	-----	------

		@	10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
--	--	---	--------------------	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
>A>	AP	+	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
>D>	AP		10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD
>A>	AP	+	10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

	@ AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jun	DISC
--	-------------	--------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	--	----------------------	--------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar	CFTG
AB	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Mar	CFTG
	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Feb	CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
AB			12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
		@	25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE
TEVA 25MG;300MG

A077369 003 Mar 30, 2012 Mar NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
AB		12.5MG;100MG	A091617 002	Feb 17, 2012	Feb	NEWA
AB		25MG;100MG	A091617 003	Feb 17, 2012	Feb	NEWA
>A>	MACLEODS PHARMS LTD	12.5MG;50MG	A202289 001	Aug 09, 2012	Jul	NEWA
>A>	AB	12.5MG;100MG	A202289 002	Aug 09, 2012	Jul	NEWA
>A>	AB	25MG;100MG	A202289 003	Aug 09, 2012	Jul	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
		12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Apr	CRLD
		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	PADDOCK LLC	12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
@		12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
@		25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

@	DOW PHARM	0.5%	A080442 002		Jun	CAHN
@		1%	A080442 003		Jun	CAHN

LOTION; TOPICAL

CETACORT

@	DOW PHARM	0.5%	A080426 002		Jun	CAHN
@		1%	A080426 001		Jun	CAHN

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000	Jan	CAHN
		NUTRACORT					
		@ DOW PHARM	0.5%	A080443 002		Jun	CAHN
AT			1%	A080443 003		Jun	CAHN
AT			2.5%	A087644 001	Aug 24, 1982	Jun	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692 001		Jan	CAHN
----	---	----------------	----	-------------	--	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT	FOUGERA PHARMS	1%;10%	A080505 001		Jan	CAHN
----	----------------	--------	-------------	--	-----	------

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

AB	+ PRECISION DERMAT	0.1%	N018514 001	Mar 31, 1982	Jun	CAHN
----	--------------------	------	-------------	--------------	-----	------

LOCOID LIPOCREAM

	+ PRECISION DERMAT	0.1%	N020769 001	Sep 08, 1997	Jun	CAHN
--	--------------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

LOCOID

	+ PRECISION DERMAT	0.1%	N022076 001	May 18, 2007	May	CAHN
--	--------------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

LOCOID

AB	+ PRECISION DERMAT	0.1%	N018652 001	Oct 29, 1982	May	CAHN
----	--------------------	------	-------------	--------------	-----	------

SOLUTION; TOPICAL

LOCOID

AT	+ PRECISION DERMAT	0.1%	N019116 001	Feb 25, 1987	Jun	CAHN
----	--------------------	------	-------------	--------------	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB	+ TARO	0.2%	A075042 001	Aug 25, 1998	Mar	CRLD
----	--------	------	-------------	--------------	-----	------

WESTCORT

	@ RANBAXY	0.2%	N017950 001		Mar	DISC
--	-----------	------	-------------	--	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB	FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+ SHIRE LLC	50MG	N011949 001		Jan	CAHN
----	-------------	------	-------------	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

	@ NESHER PHARMS	2MG	A077311 001	Nov 09, 2005	Jun	DISC
--	-----------------	-----	-------------	--------------	-----	------

	@	4MG	A077311 002	Nov 09, 2005	Jun	DISC
--	---	-----	-------------	--------------	-----	------

	@	8MG	A077311 003	Nov 09, 2005	Jun	DISC
--	---	-----	-------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ STI PHARMA LLC	10MG/5ML	A086880 001		Feb	CAHN
--	------------------	----------	-------------	--	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	@ ACTAVIS TOTOWA	10MG	A040600 001	Dec 28, 2004	Jul	CAHN
-----	------------------	------	-------------	--------------	-----	------

>D>	@	25MG	A040602 001	Dec 28, 2004	Jul	CAHN
-----	---	------	-------------	--------------	-----	------

>D>	@	50MG	A040604 001	Dec 28, 2004	Jul	CAHN
-----	---	------	-------------	--------------	-----	------

>A>	@ MIKAH PHARMA	10MG	A040600 001	Dec 28, 2004	Jul	CAHN
-----	----------------	------	-------------	--------------	-----	------

>A>	@	25MG	A040602 001	Dec 28, 2004	Jul	CAHN
-----	---	------	-------------	--------------	-----	------

>A>	@	50MG	A040604 001	Dec 28, 2004	Jul	CAHN
-----	---	------	-------------	--------------	-----	------

HYDROXYZINE PAMOATE

>D>	SUSPENSION; ORAL						
>D>	VISTARIL						
>D>	+ PFIZER	EQ 25MG HCL/5ML	N011795 001			Jul	DISC
>A>	@	EQ 25MG HCL/5ML	N011795 001			Jul	DISC

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+ HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
	IBANDRONATE SODIUM					
AB	APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
>A>	AB MUTUAL PHARM CO INC	EQ 150MG BASE	A078996 001	Aug 15, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB	WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ NORTHSTAR HLTHCARE

@

@

@ OHM LABS

400MG

600MG

800MG

400MG

A078132 001	Sep 10, 2007	Jun	DISC
A078132 002	Sep 10, 2007	Jun	DISC
A078132 003	Sep 10, 2007	Jun	DISC
A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK LLC

EQ 20MG BASE/2ML (EQ 10MG
BASE/ML)

N021903 001 Apr 13, 2006 Mar CAHN

>A> ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

>A> + AMARIN PHARMA INC

1GM

N202057 001 Jul 26, 2012 Jul NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@ TEVA PARENTERAL

@

@

5MG/VIAL

10MG/VIAL

20MG/VIAL

A065037 003	May 01, 2002	Mar	DISC
A065037 002	May 01, 2002	Mar	DISC
A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB PROSAM LABS

10MG

A040753 001 Feb 28, 2008 Feb CMFD

AB

25MG

A040752 001 Feb 28, 2008 Feb CMFD

AB

50MG

A040751 001 Feb 28, 2008 Feb CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB APOTEX INC

5%

A091308 001 Apr 06, 2012 Mar NEWA

CREAM; TOPICAL						
IMIQUIMOD						
AB	FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA
<u>INDOMETHACIN SODIUM</u>						
INJECTABLE; INJECTION						
INDOCIN						
AP	+ LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
<u>INGENOL MEBUTATE</u>						
GEL; TOPICAL						
PICATO						
	LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT</u>						
INJECTABLE; INJECTION						
HUMALOG MIX 50/50 PEN						
	@ LILLY	50 UNITS/ML;50 UNITS/ML	N021018 003	Dec 22, 1999	Jun	DISC
HUMALOG MIX 75/25 PEN						
	@ LILLY	75 UNITS/ML;25 UNITS/ML	N021017 003	Dec 22, 1999	Jun	DISC
<u>INSULIN LISPRO RECOMBINANT</u>						
INJECTABLE; INJECTION						
HUMALOG PEN						
	@ LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998	Jun	DISC
<u>IRBESARTAN</u>						
TABLET; ORAL						
AVAPRO						
AB	SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG
IRBESARTAN						
AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA
<u>IRINOTECAN HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
IRINOTECAN HYDROCHLORIDE						
AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP		100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP		500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
	@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

>A>	AN	+	BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
>D>	AN	+	BAXTER HLTHCARE CORP	99.9%	N017624 001		Jul	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB			ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Jun	CAHN
			@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

CIPHER

10MG

N021951 001 May 25, 2012 May NEWA

20MG

N021951 002 May 25, 2012 May NEWA

30MG

N021951 003 May 25, 2012 May NEWA

40MG

N021951 004 May 25, 2012 May NEWA

MYORISAN

AB			DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
----	--	--	----------------	------	-------------	--------------	-----	------

AB				20MG	A076485 002	Jan 19, 2012	Jan	NEWA
----	--	--	--	------	-------------	--------------	-----	------

AB				40MG	A076485 003	Jan 19, 2012	Jan	NEWA
----	--	--	--	------	-------------	--------------	-----	------

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

>A>	AB		MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012	Jul	NEWA
-----	----	--	------------------	-------	-------------	--------------	-----	------

IVACAFTOR

TABLET; ORAL

KALYDECO

+ VERTEX PHARMS 150MG

N203188 001 Jan 31, 2012 Jan NEWA

IVERMECTIN

LOTION; TOPICAL

SKLICE

+ SANOFI PASTEUR 0.5%

N202736 001 Feb 07, 2012 Feb NEWA

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB			FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	--	--	----------------	----	-------------	--------------	-----	------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

>A>			DORADO PHARMA	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
-----	--	--	---------------	------	-------------	--------------	-----	------

>A>	AB			50MG	A074014 002	Jan 29, 1993	Jul	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>A>	AB			75MG	A074014 003	Jan 29, 1993	Jul	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>D>			HERITAGE PHARMS INC	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
-----	--	--	---------------------	------	-------------	--------------	-----	------

>D>	AB			50MG	A074014 002	Jan 29, 1993	Jul	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>D>	AB			75MG	A074014 003	Jan 29, 1993	Jul	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL									
KETOPROFEN									
AB	ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10,	1997	Jun	CAHN	
<u>LABETALOL HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
LABETALOL HYDROCHLORIDE									
AP	GLAND PHARMA LTD	5MG/ML	A090699	001	Apr 03,	2012	Mar	NEWA	
TABLET; ORAL									
LABETALOL HYDROCHLORIDE									
AB	PAR FORM	100MG	A200908	001	Jul 10,	2012	Jun	NEWA	
AB		200MG	A200908	002	Jul 10,	2012	Jun	NEWA	
AB		300MG	A200908	003	Jul 10,	2012	Jun	NEWA	
<u>LACTULOSE</u>									
FOR SOLUTION; ORAL									
LACTULOSE									
+	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10,	1997	Jun	CAHN	
+		20GM/PACKET	A074712	002	Dec 10,	1997	Jun	CAHN	
SOLUTION; ORAL									
LACTULOSE									
AA	FRESENIUS KABI	10GM/15ML	A090503	001	Jan 25,	2012	Jan	NEWA	
SOLUTION; ORAL, RECTAL									
LACTULOSE									
AA	FRESENIUS KABI	10GM/15ML	A090502	001	Jan 25,	2012	Jan	NEWA	
<u>LAMIVUDINE; ZIDOVUDINE</u>									
TABLET; ORAL									
LAMIVUDINE AND ZIDOVUDINE									
AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418	001	May 15,	2012	Apr	NEWA	
AB	LUPIN LTD	150MG;300MG	A090246	001	May 15,	2012	Apr	NEWA	
<u>LAMOTRIGINE</u>									
TABLET; ORAL									
LAMOTRIGINE									
AB	GLENMARK GENERICS	25MG	A090169	001	May 12,	2012	Apr	NEWA	
AB		100MG	A090169	002	May 12,	2012	Apr	NEWA	
AB		150MG	A090169	003	May 12,	2012	Apr	NEWA	
AB		200MG	A090169	004	May 12,	2012	Apr	NEWA	
<u>LANREOTIDE ACETATE</u>									
INJECTABLE; SUBCUTANEOUS									
SOMATULINE DEPOT									
+	IPSEN INC	EQ 60MG BASE	N022074	001	Aug 30,	2007	Apr	CAHN	
+		EQ 90MG BASE	N022074	002	Aug 30,	2007	Apr	CAHN	
+		EQ 120MG BASE	N022074	003	Aug 30,	2007	Apr	CAHN	
+	IPSEN PHARMA	EQ 60MG BASE	N022074	001	Aug 30,	2007	May	CAHN	
+		EQ 90MG BASE	N022074	002	Aug 30,	2007	May	CAHN	
+		EQ 120MG BASE	N022074	003	Aug 30,	2007	May	CAHN	
<u>LANSOPRAZOLE</u>									
CAPSULE, DELAYED REL PELLETS; ORAL									
PREVACID									
AB	TAKEDA PHARMS USA	15MG	N020406	001	May 10,	1995	Mar	CAHN	
AB	+	30MG	N020406	002	May 10,	1995	Mar	CAHN	

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@ TEVA PHARMS

15MG

A078730 001 Oct 15, 2010 Mar DISC

@

30MG

A078730 002 Oct 15, 2010 Mar DISC

PREVACID

TAKEDA PHARMS USA

15MG

N021428 001 Aug 30, 2002 Mar CTEC

+

30MG

N021428 002 Aug 30, 2002 Mar CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

@ SHIRE LLC

EQ 250MG BASE

N021468 001 Oct 26, 2004 Feb CAHN

EQ 500MG BASE

N021468 002 Oct 26, 2004 Feb CAHN

EQ 750MG BASE

N021468 003 Nov 23, 2005 Feb CAHN

+

EQ 1GM BASE

N021468 004 Nov 23, 2005 Feb CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

AB APOTEX INC

2.5MG

A091303 001 Apr 19, 2012 Apr NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ TEVA PARENTERAL

EQ 50MG BASE/VIAL

A081278 001 Sep 28, 1993 Mar DISC

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+ ABBOTT ENDOCRINE

3.75MG/VIAL

N020011 001 Oct 22, 1990 May CAHN

+

7.5MG/VIAL

N019732 001 Jan 26, 1989 May CAHN

+

11.25MG/VIAL

N020708 001 Mar 07, 1997 May CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP APP PHARMS LLC

500MG/5ML (100MG/ML)

A090813 001 May 26, 2010 May CAHN

AP HOSPIRA INC

500MG/ML (100MG/ML)

A202869 001 Apr 06, 2012 Mar NEWA

>D> AP INNOPHARMA LLC

500MG/5ML (100MG/ML)

A091485 001 Aug 05, 2011 Jul CAHN

AP PHARMAFORCE

500MG/5ML (100MG/ML)

A202143 001 Jan 31, 2012 Jan NEWA

>A> AP X GEN PHARMS

500MG/5ML (100MG/ML)

A091485 001 Aug 05, 2011 Jul CAHN

SOLUTION; ORAL

LEVETIRACETAM

AA HI-TECH PHARMACAL

100MG/ML

A090601 001 Feb 28, 2012 Feb NEWA

AA VINTAGE PHARMS

100MG/ML

A090079 001 Apr 11, 2012 Mar NEWA

TABLET; ORAL

LEVETIRACETAM

>D> AB BIOKEY

500MG

A090906 001 Nov 05, 2010 Jul CAHN

>A> AB LOTUS PHARM CO LTD

500MG

A090906 001 Nov 05, 2010 Jul CAHN

AB WATSON LABS INC

250MG

A078797 002 Jan 15, 2009 Apr NEWA

AB

500MG

A078797 003 Jan 15, 2009 Apr NEWA

AB

750MG

A078797 004 Jan 15, 2009 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB BOCA PHARMA

500MG

A201464 001 May 25, 2012 May NEWA

AB

750MG

A201464 002 May 25, 2012 May NEWA

TABLET, EXTENDED RELEASE; ORAL							
LEVETIRACETAM							
AB	TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012	May	NEWA	
AB		750MG	A091338 002	May 29, 2012	May	NEWA	
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
TABLET; ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
AB	HETERO LABS LTD III	5MG	A091264 001	Jun 29, 2012	Jun	NEWA	
<u>LEVOFLOXACIN</u>							
TABLET; ORAL							
LEVOFLOXACIN							
AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA	
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA	
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA	
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA	
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA	
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA	
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA	
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA	
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA	
<u>LEVOLEUCOVORIN CALCIUM</u>							
SOLUTION; IV (INFUSION)							
FUSILEV							
	@ SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 29, 2011	Jun	DISC	
<u>LEVONORGESTREL</u>							
TABLET; ORAL							
LEVONORGESTREL							
AB	WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA	
PLAN B							
	@ TEVA BRANDED PHARM	0.75MG	N021045 001	Jul 28, 1999	May	CAHN	
AB	+	0.75MG	N021045 002	Aug 24, 2006	May	CAHN	
PLAN B ONE-STEP							
AB	+	DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
XYLOCAINE DENTAL							
	@ DENTSPLY PHARM	2%	N021380 001		May	DISC	
<u>LIDOCAINE; PRILOCAINE</u>							
CREAM; TOPICAL							
LIDOCAINE AND PRILOCAINE							
AB	FOUGERA PHARMS	2.5%; 2.5%	A076453 001	Aug 18, 2003	Jan	CAHN	
<u>LIDOCAINE; TETRACAINE</u>							
CREAM; TOPICAL							
PLIAGLIS							
+	GALDERMA LABS LP	7%; 7%	N021717 001	Jun 29, 2006	Jun	CTNA	

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

BOEHRINGER INGELHEIM 2.5MG;500MG

N201281 001 Jan 30, 2012 Jan NEWA

2.5MG;850MG

N201281 002 Jan 30, 2012 Jan NEWA

+

2.5MG;1GM

N201281 003 Jan 30, 2012 Jan NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP TEVA PHARMS 200MG/100ML

A200222 001 Jun 22, 2012 Jun NEWA

ZYVOX

AP + PHARMACIA AND UPJOHN 200MG/100ML

N021131 001 Apr 18, 2000 Jun CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB MYLAN PHARMS INC 300MG

A202288 001 Jun 29, 2012 Jun NEWA

>A> AB 450MG

A202219 001 Aug 08, 2012 Jul NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

BRISTOL MYERS SQUIBB 10MG

N017588 001 Jun CMFD

@ 10MG

N017588 001 May DISC

40MG

N017588 002 Jun CMFD

@ 40MG

N017588 002 May DISC

+ 100MG

N017588 003 Jun CMFD

@ 100MG

N017588 003 May DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA HI-TECH PHARMA CO 2MG/ML

A200169 001 Jan 30, 2012 Jan NEWA

INJECTABLE; INJECTION

LORAZEPAM

@ BEDFORD 2MG/ML

A077076 001 Jul 13, 2005 Jun DISC

@ 4MG/ML

A077076 002 Jul 13, 2005 Jun DISC

@ HOSPIRA 2MG/ML

A074300 001 Apr 12, 1994 Jun DISC

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

>D> + ARENA PHARMS INC 10MG

N022529 001 Jun 27, 2012 Jul CAHN

+ 10MG

N022529 001 Jun 27, 2012 Jun NEWA

>A> + EISAI INC 10MG

N022529 001 Jun 27, 2012 Jul CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB MACLEODS PHARMS LTD 25MG

A202230 001 May 30, 2012 May NEWA

AB 50MG

A202230 002 May 30, 2012 May NEWA

AB 100MG

A202230 003 May 30, 2012 May NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

>D>	@ ACTAVIS TOTOWA	EQ 5MG BASE	A076868 001	Aug 04, 2005	Jul	CAHN
>D>	@	EQ 10MG BASE	A076868 002	Aug 04, 2005	Jul	CAHN
>D>	@	EQ 25MG BASE	A076868 003	Aug 04, 2005	Jul	CAHN
>D>	@	EQ 50MG BASE	A076868 004	Aug 04, 2005	Jul	CAHN
>A>	@ MIKAH PHARMA	EQ 5MG BASE	A076868 001	Aug 04, 2005	Jul	CAHN
>A>	@	EQ 10MG BASE	A076868 002	Aug 04, 2005	Jul	CAHN
>A>	@	EQ 25MG BASE	A076868 003	Aug 04, 2005	Jul	CAHN
>A>	@	EQ 50MG BASE	A076868 004	Aug 04, 2005	Jul	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746 001	Mar 06, 2012	Apr	NEWA
---	----------------	-------	-------------	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Apr	NEWA
+		40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

@	EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004	Jun	DISC
---	------------	------------	-------------	--------------	-----	------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+	MYLAN LLC	EQ 85MG BASE/GM	N016763 001		Jun	CAHN
---	-----------	-----------------	-------------	--	-----	------

FOR SOLUTION; TOPICAL

SULFAMYLON

+	MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jun	CAHN
---	-----------	----	-------------	--------------	-----	------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@	SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009	Jun	DISC
---	----------	------------------	-------------	--------------	-----	------

@		343MG;40MG;750MG	N022456 002	Dec 04, 2009	Jun	DISC
---	--	------------------	-------------	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
--	---------	----------------------	-------------	--------------	-----	------

		40GM/1000ML (40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA
--	--	-----------------------	-------------	--------------	-----	------

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
----	------------------	------	-------------	--------------	-----	------

AT	SUVEN LIFE	0.5%	A091559 001	May 23, 2012	May	NEWA
----	------------	------	-------------	--------------	-----	------

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May	CAHN
---	---------------	----------------------------	---------	-----	--------------	-----	------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294	001	Apr 13, 2012	Mar	NEWA
----	-----------------	--------	---------	-----	--------------	-----	------

AA		25MG	A200294	002	Apr 13, 2012	Mar	NEWA
----	--	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552	001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@	ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012	Mar	DISC
---	-----------------	-----	---------	-----	--------------	-----	------

AB		5MG	A090044	001	Mar 12, 2012	Feb	NEWA
----	--	-----	---------	-----	--------------	-----	------

@		10MG	A090044	002	Mar 12, 2012	Mar	DISC
---	--	------	---------	-----	--------------	-----	------

AB		10MG	A090044	002	Mar 12, 2012	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

NAMENDA

	FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CTEC
--	-------------	-----	---------	-----	--------------	-----	------

AB		5MG	N021487	001	Oct 16, 2003	Feb	CTEC
----	--	-----	---------	-----	--------------	-----	------

+		10MG	N021487	002	Oct 16, 2003	Mar	CTEC
---	--	------	---------	-----	--------------	-----	------

AB	+	10MG	N021487	002	Oct 16, 2003	Feb	CTEC
----	---	------	---------	-----	--------------	-----	------

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@	DENTSPLY PHARM	3%	A088653	001	Aug 21, 1984	May	DISC
---	----------------	----	---------	-----	--------------	-----	------

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@	AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999	Jun	DISC
---	-------------	----------	---------	-----	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

>A>	@	APTALIS PHARMA US	500MG	N021252	001	Jan 05, 2001	Jul	CAHN
-----	---	-------------------	-------	---------	-----	--------------	-----	------

>A>			1GM	N021252	002	Nov 05, 2004	Jul	CAHN
-----	--	--	-----	---------	-----	--------------	-----	------

>D>	@	AXCAN	500MG	N021252	001	Jan 05, 2001	Jul	CAHN
-----	---	-------	-------	---------	-----	--------------	-----	------

>D>	+		1GM	N021252	002	Nov 05, 2004	Jul	CAHN
-----	---	--	-----	---------	-----	--------------	-----	------

ROWASA

@	MEDA PHARMS	500MG	N019919	001	Dec 18, 1990	Jan	CAHN
---	-------------	-------	---------	-----	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
----	---------------------	----------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
----	-----------------	-------	-------------	--------------	-----	------

AB		850MG	A090888 002	Mar 12, 2012	Feb	NEWA
----	--	-------	-------------	--------------	-----	------

AB		1GM	A090888 003	Mar 12, 2012	Feb	NEWA
----	--	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>A>	AB1	AUROBINDO PHARMA LTD	500MG	A079118 001	Jul 20, 2012	Jul	NEWA
-----	-----	----------------------	-------	-------------	--------------	-----	------

>A>	AB		750MG	A079118 002	Jul 20, 2012	Jul	NEWA
-----	----	--	-------	-------------	--------------	-----	------

	AB1	INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
--	-----	-------------------	-------	-------------	--------------	-----	------

>A>	AB2	MYLAN PHARMS INC	500MG	A200690 001	Aug 01, 2012	Jul	NEWA
-----	-----	------------------	-------	-------------	--------------	-----	------

>A>	AB		1GM	A200690 002	Aug 01, 2012	Jul	NEWA
-----	----	--	-----	-------------	--------------	-----	------

	@	RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Apr	DISC
--	---	------------------	-------	-------------	--------------	-----	------

	@		750MG	A077211 001	Jun 29, 2005	Apr	DISC
--	---	--	-------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010	Apr	CAIN
--	----------------------	-------------------	-------------	--------------	-----	------

		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN
--	--	-------------------	-------------	--------------	-----	------

+		1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010	Apr	CAIN
---	--	-----------------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007	May	CAHN
--	-------------------	--------------------	-------------	--------------	-----	------

+		1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007	May	CAHN
---	--	------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
--	-------------------	--------------------	-------------	--------------	-----	------

		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
--	--	------------------	-------------	--------------	-----	------

+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA
---	--	-------------------	-------------	--------------	-----	------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
----	-------------	-----	-------------	--------------	-----	------

AB		10MG	A202068 002	Mar 07, 2012	Feb	NEWA
----	--	------	-------------	--------------	-----	------

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001		Mar	CMFD
----	----------------	-------	-------------	--	-----	------

AA		750MG	A086988 001		Mar	CMFD
----	--	-------	-------------	--	-----	------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
----	----------------	------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA
AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

2.5MG

N012524 001

Mar DISC

@

5MG

N012524 004

Mar DISC

METHYLCLOTHIAZIDE

AB	+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	---	------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

>D>	BX	UCB INC	10MG	N021259 003	May 27, 2003	Jul	CFTG
>A>	AB		10MG	N021259 003	May 27, 2003	Jul	CFTG
>D>	BX		20MG	N021259 001	Apr 03, 2001	Jul	CFTG
>A>	AB2		20MG	N021259 001	Apr 03, 2001	Jul	CFTG
>D>	BX		30MG	N021259 002	Jun 19, 2003	Jul	CFTG
>A>	AB2		30MG	N021259 002	Jun 19, 2003	Jul	CFTG
>D>	BX		40MG	N021259 004	Feb 19, 2006	Jul	CFTG
>A>	AB2		40MG	N021259 004	Feb 19, 2006	Jul	CFTG
>D>			50MG	N021259 005	Feb 19, 2006	Jul	CFTG
>A>	AB		50MG	N021259 005	Feb 19, 2006	Jul	CFTG
>D>	+		60MG	N021259 006	Feb 19, 2006	Jul	CFTG
>A>	AB	+	60MG	N021259 006	Feb 19, 2006	Jul	CFTG

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS	20MG	A078458 001	Dec 01, 2011	Jul	CTEC
>A>	AB1		20MG	A078458 001	Dec 01, 2011	Jul	CTEC
>D>	AB		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
>A>	AB1		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
>D>	AB		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
>A>	AB1		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
>D>	AB	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jul	CTEC
>A>	AB1		20MG	A079031 001	Jul 13, 2012	Jul	CTEC
	AB		20MG	A079031 001	Jul 13, 2012	Jun	NEWA
>D>	AB		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
>A>	AB1		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
	AB		30MG	A079031 002	Jul 13, 2012	Jun	NEWA
>D>	AB		40MG	A079031 003	Jul 13, 2012	Jul	CTEC
>A>	AB1		40MG	A079031 003	Jul 13, 2012	Jul	CTEC
	AB		40MG	A079031 003	Jul 13, 2012	Jun	NEWA
>A>	AB	TEVA PHARMS	10MG	A077707 001	Jul 19, 2012	Jul	NEWA
>A>	AB2		20MG	A077707 002	Jul 19, 2012	Jul	NEWA
>A>	AB2		30MG	A077707 003	Jul 19, 2012	Jul	NEWA
>A>	AB2		40MG	A078873 001	Jul 19, 2012	Jul	NEWA
>A>	AB		50MG	A078873 002	Jul 19, 2012	Jul	NEWA
>A>	AB		60MG	A078873 003	Jul 19, 2012	Jul	NEWA
RITALIN LA							
>D>	AB	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
>A>	AB1		20MG	N021284 001	Jun 05, 2002	Jul	CTEC
>D>	AB		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
>A>	AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
>D>	AB	+	40MG	N021284 003	Jun 05, 2002	Jul	CTEC
>A>	AB1	+	40MG	N021284 003	Jun 05, 2002	Jul	CTEC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

>D>	AB	UCB INC	10MG	A040306 001	Oct 20, 1999	Jul	DISC
>A>	@		10MG	A040306 001	Oct 20, 1999	Jul	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

@	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
@		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC
@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
---	-----------------	----------------	-------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>A>	AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012	Jul	NEWA
>A>	AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012	Jul	NEWA
		@ NESHER PHARMS	EQ 100MG TARTRATE	A076640 002	May 18, 2007	Jun	DISC
		@	EQ 200MG TARTRATE	A076640 001	May 18, 2007	Jun	DISC
>A>	AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012	Jul	NEWA
>A>	AB		EQ 200MG BASE	A078889 002	Aug 15, 2012	Jul	NEWA

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
		NORITATE					
	+	VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
---	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METOPIRONE

@	HRA PHARMA	250MG	N012911 001		Jun	CAHN
---	------------	-------	-------------	--	-----	------

METYROSINE

CAPSULE; ORAL

DEMSE

+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
---	----------------------	-------	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP			EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB		SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+		5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB			10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
---	----------------	-------	-------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
	@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN
AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> XIMINO

>A>	RANBAXY LABS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012	Jul	NEWA
>A>		EQ 67.5MG BASE	N201922 002	Jul 11, 2012	Jul	NEWA
>A>		EQ 90MG BASE	N201922 003	Jul 11, 2012	Jul	NEWA
>A>		EQ 112.5MG BASE	N201922 004	Jul 11, 2012	Jul	NEWA
>A>	+	EQ 135MG BASE	N201922 005	Jul 11, 2012	Jul	NEWA

INJECTABLE; INJECTION

MINOCIN

+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN
---	------------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

MINOCIN

@	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN
---	------------------	------------------	-------------	--	-----	------

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

	APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA
+		50MG	N202611 002	Jun 28, 2012	Jun	NEWA

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

>A>	AB	NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA
>A>	AB		0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
---	---------------	------------	-------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC
@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC
@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	Jun	CAHN
---	---------------------	----------------	-------------	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

AB	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012	Jun	NEWA
----	------------------	-------	-------------	--------------	-----	------

TABLET; ORAL						
MODAFINIL						
AB	MYLAN PHARMS INC	200MG	A076594	002	Jul 16, 2012	Jun NEWA
PROVIGIL						
AB	CEPHALON	100MG	N020717	001	Dec 24, 1998	Jun CFTG
AB	+	200MG	N020717	002	Dec 24, 1998	Jun CFTG
<u>MOMETASONE FUROATE</u>						
CREAM; TOPICAL						
ELOCON						
AB	+	MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987 Jun CAHN
MOMETASONE FUROATE						
AB	FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005	Jan CAHN
LOTION; TOPICAL						
ELOCON						
>A>	AB	+	MERCK SHARP DOHME	0.1%	N019796	001 Mar 30, 1989 Jul CAHN
>D>	AB	+	SCHERING	0.1%	N019796	001 Mar 30, 1989 Jul CAHN
MOMETASONE FUROATE						
AB	FOUGERA PHARMS	0.1%	A075919	001	Nov 29, 2007	Jan CAHN
OINTMENT; TOPICAL						
ELOCON						
AB	+	MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987 May CAHN
MOMETASONE FUROATE						
AB	FOUGERA PHARMS	0.1%	A077061	001	Mar 28, 2005	Jan CAHN
<u>MONTELUKAST SODIUM</u>						
GRANULE; ORAL						
MONTELUKAST SODIUM						
>A>	AB	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012 Jul NEWA
SINGULAIR						
>D>	+	MERCK	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002 Jul CFTG
>A>	AB	+	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002 Jul CFTG
TABLET; ORAL						
MONTELUKAST SODIUM						
>A>	AB	APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012 Jul NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468	001	Aug 03, 2012 Jul NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 10MG BASE	A201582	001	Aug 06, 2012 Jul NEWA
>A>	AB	ENDO PHARMS	EQ 10MG BASE	A091576	001	Aug 03, 2012 Jul NEWA
>A>	AB	GLENMARK GENERICS	EQ 10MG BASE	A090926	001	Aug 03, 2012 Jul NEWA
>A>	AB	KUDCO IRELAND	EQ 10MG BASE	A201522	001	Aug 03, 2012 Jul NEWA
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012 Jul NEWA
>A>	AB	ROXANE	EQ 10MG BASE	A090655	001	Aug 03, 2012 Jul NEWA
>A>	AB	SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012 Jul NEWA
>A>	AB	TEVA PHARMS	EQ 10MG BASE	A078605	001	Aug 03, 2012 Jul NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 10MG BASE	A201515	001	Aug 03, 2012 Jul NEWA
SINGULAIR						
>D>	+	MERCK	EQ 10MG BASE	N020829	002	Feb 20, 1998 Jul CFTG
>A>	AB	+	EQ 10MG BASE	N020829	002	Feb 20, 1998 Jul CFTG
TABLET, CHEWABLE; ORAL						
MONTELUKAST SODIUM						
>A>	AB	APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012 Jul NEWA
>A>	AB		EQ 5MG BASE	A201508	002	Aug 03, 2012 Jul NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096	001	Aug 03, 2012 Jul NEWA
>A>	AB		EQ 5MG BASE	A202096	002	Aug 03, 2012 Jul NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 4MG BASE	A201581	001	Aug 06, 2012 Jul NEWA
>A>	AB		EQ 5MG BASE	A201581	002	Aug 06, 2012 Jul NEWA

TABLET, CHEWABLE; ORAL

>A> MONTELUKAST SODIUM

>A>	AB	ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
>A>	AB	KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
>A>	AB	ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
>A>	AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
>A>	AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA

SINGULAIR

>D>		MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
>A>	AB		EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
>D>	+		EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG
>A>	AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

>A>		ACTAVIS ELIZABETH	40MG	N020616 009	Jul 09, 2012	Jul	NEWA
>A>			70MG	N020616 010	Jul 09, 2012	Jul	NEWA
>A>			130MG	N020616 011	Jul 09, 2012	Jul	NEWA
>A>			150MG	N020616 012	Jul 09, 2012	Jul	NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN

INFUMORPH

+	HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
+		25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

>A>	AA	PADDOCK LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul	NEWA
-----	----	-------------	-----------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
AB			30MG	A078761 002	May 11, 2012	Apr	NEWA
AB			60MG	A078761 003	May 11, 2012	Apr	NEWA
AB			100MG	A078761 004	May 11, 2012	Apr	NEWA
AB			200MG	A078761 005	May 11, 2012	Apr	NEWA

ORAMORPH SR

@	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
@		30MG	N019977 001	Aug 15, 1991	May	DISC
@		60MG	N019977 002	Aug 15, 1991	May	DISC
@		100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCIIN

OINTMENT; TOPICAL

MUPIROCIIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD
----	--	-------	-------------	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	HIKMA MAPLE	0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN
---	-------------	----------	-------------	--------------	-----	------

@		0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
---	--	----------	-------------	--------------	-----	------

@		0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
---	--	----------	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

@	HIKMA MAPLE	0.02MG/ML	A071272 001	May 24, 1988	Jun	CAHN
---	-------------	-----------	-------------	--------------	-----	------

@		1MG/ML	A071273 001	May 24, 1988	Jun	CAHN
---	--	--------	-------------	--------------	-----	------

@		1MG/ML	A071274 001	May 24, 1988	Jun	CAHN
---	--	--------	-------------	--------------	-----	------

@		1MG/ML	A071287 001	May 24, 1988	Jun	CAHN
---	--	--------	-------------	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN
----	-------------------	---------------	-------------	--	-----	------

ANAPROX DS

AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN
----	---	-------------------	---------------	-------------	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
---	--------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
----	------------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
----	--	---------------	-------------	--------------	-----	------

AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
----	-----------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA
----	--	---------------	-------------	--------------	-----	------

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

>D>	AB	TEVA PHARMS	60MG	A077467 001	Sep 09, 2009	Jul	DISC
>A>		@	60MG	A077467 001	Sep 09, 2009	Jul	DISC
>D>	AB		120MG	A077467 002	Sep 09, 2009	Jul	DISC
>A>		@	120MG	A077467 002	Sep 09, 2009	Jul	DISC

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA		AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
----	--	-----------	----------	-------------	--------------	-----	------

VIRAMUNE

AA	+	BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG
----	---	----------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB		APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
AB		AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
AB		CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
AB		HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
AB		MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
AB		MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
AB		MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
AB		PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
AB		SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May	NEWA
AB		STRIDES	200MG	A078195 001	May 22, 2012	May	NEWA

VIRAMUNE

AB	+	BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May	CFTG
----	---	----------------------	-------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1		ACTAVIS	90MG	A077899 003	May 25, 2012	May	NEWA
-----	--	---------	------	-------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

>A>	AB	ALMATICA	25MG	N016620 003		Jul	CAHN
>A>	AB		50MG	N016620 001		Jul	CAHN
>A>	AB	+	100MG	N016620 002		Jul	CAHN
>D>	AB	ALVOGEN	25MG	N016620 003		Jul	CAHN
>D>	AB		50MG	N016620 001		Jul	CAHN
>D>	AB	+	100MG	N016620 002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

>A>	AB	+	ALMATICA	75MG;25MG	N020064 001	Dec 24, 1991	Jul	CAHN
>D>	AB	+	ALVOGEN	75MG;25MG	N020064 001	Dec 24, 1991	Jul	CAHN

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

		@	RANBAXY LABS LTD	75MG;25MG	A076951 001	Mar 30, 2005	Apr	DISC
--	--	---	------------------	-----------	-------------	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

>D>	AB1	GRACEWAY	0.1MG/HR	A089771 001	Aug 30, 1996	Jul	CAHN
>D>	AB1		0.2MG/HR	A089772 001	Aug 30, 1996	Jul	CAHN
>D>	AB1		0.4MG/HR	A089773 001	Aug 30, 1996	Jul	CAHN
>D>	AB1		0.6MG/HR	A089774 001	Aug 30, 1996	Jul	CAHN
>A>	AB1	MEDICIS	0.1MG/HR	A089771 001	Aug 30, 1996	Jul	CAHN
>A>	AB1		0.2MG/HR	A089772 001	Aug 30, 1996	Jul	CAHN
>A>	AB1		0.4MG/HR	A089773 001	Aug 30, 1996	Jul	CAHN
>A>	AB1		0.6MG/HR	A089774 001	Aug 30, 1996	Jul	CAHN

OINTMENT; INTRA-ANAL
RECTIV

+	APTALIS PHARMA	0.4%	N021359 001	Jun 21, 2011	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

@	SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988	Mar	DISC
@		300MG	N019508 002	Apr 12, 1988	Mar	DISC

NIZATIDINE

@	MYLAN PHARMS INC	150MG	A075934 001	Jul 09, 2002	Apr	DISC
AB +		300MG	A075806 002	Jul 05, 2002	Apr	CRLD
@		300MG	A075934 002	Jul 09, 2002	Apr	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	May	CAHN
AP	SINTETICA	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	Mar	NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

>A>	AB	AMNEAL PHARMS	5MG	A200275 001	Jul 30, 2012	Jul	NEWA
-----	----	---------------	-----	-------------	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129 001		Jan	CAHN
----	----------------	------------------	-------------	--	-----	------

OINTMENT; TOPICAL

NYSTATIN

AT +	FOUGERA PHARMS	100,000 UNITS/GM	A062124 002	Sep 23, 1982	Jan	CAHN
------	----------------	------------------	-------------	--------------	-----	------

POWDER; TOPICAL

NYSTATIN

@	NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006	Jun	DISC
---	---------------	------------------	-------------	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Jun	CAHN
---	------------------	-----------------------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

@	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Jun	CAHN
---	------------------	-----------------------	-------------	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD

200MG

A076220 001 Sep 02, 2003 Apr DISC

@

300MG

A076220 002 Sep 02, 2003 Apr DISC

@

400MG

A076220 003 Sep 02, 2003 Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP PHARMAFORCE

10MG/VIAL

A201741 001 Mar 20, 2012 Mar NEWA

AP SANDOZ INC

10MG/VIAL

A201588 001 Oct 24, 2011 Mar CAHN

TABLET; ORAL

OLANZAPINE

AB APOTEX INC

2.5MG

A090798 001 Apr 23, 2012 Apr NEWA

AB

5MG

A090798 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A090798 003 Apr 23, 2012 Apr NEWA

AB

10MG

A090798 004 Apr 23, 2012 Apr NEWA

AB

15MG

A090798 005 Apr 23, 2012 Apr NEWA

AB

20MG

A090798 006 Apr 23, 2012 Apr NEWA

AB AUROBINDO PHARMA LTD

2.5MG

A202050 001 Apr 23, 2012 Apr NEWA

AB

5MG

A202050 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A202050 003 Apr 23, 2012 Apr NEWA

AB

10MG

A202050 004 Apr 23, 2012 Apr NEWA

AB

15MG

A202050 005 Apr 23, 2012 Apr NEWA

AB

20MG

A202050 006 Apr 23, 2012 Apr NEWA

AB DR REDDYS LABS LTD

2.5MG

A076255 001 Apr 23, 2012 Apr NEWA

AB

5MG

A076255 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A076255 003 Apr 23, 2012 Apr NEWA

AB

10MG

A076255 004 Apr 23, 2012 Apr NEWA

AB

15MG

A076133 001 Apr 23, 2012 Apr NEWA

AB MYLAN

2.5MG

A076866 001 Apr 23, 2012 Apr NEWA

AB

5MG

A076866 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A076866 003 Apr 23, 2012 Apr NEWA

AB

10MG

A076866 004 Apr 23, 2012 Apr NEWA

AB

15MG

A076866 005 Apr 23, 2012 Apr NEWA

AB

20MG

A076866 006 Apr 23, 2012 Apr NEWA

AB ORCHID HLTHCARE

2.5MG

A202287 001 Apr 23, 2012 Apr NEWA

AB

5MG

A202287 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A202287 003 Apr 23, 2012 Apr NEWA

AB

10MG

A202287 004 Apr 23, 2012 Apr NEWA

AB

15MG

A202287 005 Apr 23, 2012 Apr NEWA

AB

20MG

A202287 006 Apr 23, 2012 Apr NEWA

AB SUN PHARM INDS

2.5MG

A091038 001 Apr 23, 2012 Apr NEWA

AB

5MG

A091038 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A091038 003 Apr 23, 2012 Apr NEWA

AB

10MG

A091038 004 Apr 23, 2012 Apr NEWA

AB

15MG

A091038 005 Apr 23, 2012 Apr NEWA

AB

20MG

A091038 006 Apr 23, 2012 Apr NEWA

AB TORRENT PHARMS LTD

2.5MG

A091434 001 Apr 23, 2012 Apr NEWA

AB

5MG

A091434 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A091434 003 Apr 23, 2012 Apr NEWA

AB

10MG

A091434 004 Apr 23, 2012 Apr NEWA

AB

15MG

A091434 005 Apr 23, 2012 Apr NEWA

AB

20MG

A091434 006 Apr 23, 2012 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@ NESHER PHARMS

4MG

A077717 001 Jun 25, 2007 Jun DISC

@

8MG

A077717 002 Jun 25, 2007 Jun DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

>A>	AB	CNTY LINE PHARMS	100MG	A040249 001	Jan 29, 1999	Jul	CAHN
>A>	AB	INVAGEN PHARMS	100MG	A091158 001	Jul 27, 2012	Jul	NEWA
>D>	AB	KIEL	100MG	A040249 001	Jan 29, 1999	Jul	CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE

EQ 6MG BASE/ML

N021246 002 Mar 21, 2011 Jan CRLD

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

>A>	AP	ACTAVIS TOTOWA	50MG/VIAL	A078803 001	Aug 08, 2012	Jul	NEWA
>A>	AP		100MG/VIAL	A078803 002	Aug 08, 2012	Jul	NEWA
>A>	AP	ONCO THERAPIES LTD	50MG/VIAL	A200979 001	Aug 08, 2012	Jul	NEWA

INJECTABLE; IV (INFUSION)

OXALIPLATIN

>A>	AP	ONCO THERAPIES LTD	50MG/10ML (5MG/ML)	A091358 001	Aug 07, 2012	Jul	NEWA
>A>	AP		100MG/20ML (5MG/ML)	A091358 002	Aug 07, 2012	Jul	NEWA
>A>	AP		100MG/VIAL	A200979 002	Aug 08, 2012	Jul	NEWA
	AP	+ TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
	AP	+	100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

	+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
--	---	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

	+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
	+		600MG	A086742 001		Jun	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

	+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
	+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS 5MG

N017577 001 Mar DISC

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	COASTAL PHARMS	5MG	A203107 001	Jul 26, 2012	Jul	NEWA
>D>	+	LEHIGH VALLEY	5MG	N200534 001	Oct 20, 2010	Jul	CFTG
>A>	AB	+	5MG	N200534 001	Oct 20, 2010	Jul	CFTG

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

>D>		+	LEHIGH VALLEY	100MG/5ML	N200535 001	Oct 20, 2010	Jul	CFTG
>A>	AA	+		100MG/5ML	N200535 001	Oct 20, 2010	Jul	CFTG
		+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
>A>	AA			100MG/5ML	A202537 001	Jul 30, 2012	Jul	NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS 5MG

N021610 001 Jun 22, 2006 May DISC

@ 10MG

N021610 002 Jun 22, 2006 May DISC

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS	20MG	N021610 003	Jun 22, 2006	May	DISC
@	30MG	N021610 007	Feb 29, 2008	May	DISC
@	40MG	N021610 004	Jun 22, 2006	May	DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

5MG	A079087 001	Jun 14, 2010	May	CTEC
10MG	A079087 003	Jun 14, 2010	May	CTEC
20MG	A079087 005	Jun 14, 2010	May	CTEC
30MG	A079087 006	Jul 22, 2010	May	CTEC
40MG	A079087 007	Jun 14, 2010	May	CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	Jan	DISC
@	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Mar	CAHN
-----------------	--------	-------------	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS	30MG/VIAL	N020036 001	Oct 31, 1991	Mar	DISC
------------	-----------	-------------	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725 004	Jul 12, 2011	Jun	NEWA
30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Feb	CAHN
60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Feb	CAHN
+ 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Feb	CAHN

PERTZYE

DIGESTIVE CARE INC

30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175 001	May 17, 2012	May	NEWA
+ 60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175 002	May 17, 2012	May	NEWA

ULTRESA

APTALIS PHARMA US

27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222 001	Mar 01, 2012	Mar	NEWA
41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222 002	Mar 01, 2012	Mar	NEWA
+ 46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222 003	Mar 01, 2012	Mar	NEWA

ZENPEP

APTALIS PHARMA US

16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210 005	Jun 15, 2011	Apr	NEWA
109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009	Apr	CRLD
+ 136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210 006	Jul 13, 2011	Apr	NEWA

TABLET; ORAL

VIOKACE

	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012	Mar	NEWA
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	APOTEX INC	EQ 20MG BASE	A090807 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A090807 002	May 02, 2012	Apr	NEWA
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
AB		EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA
AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
----	------	-----	-------------	--------------	-----	------

TABLET; ORAL

ACEON

AB	XOMA	4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
----	---	------------------	------	-------------	--	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

AB	ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA
----	--------	------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

>D>	@	ACTAVIS TOTOWA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
>D>	@		30MG	A040227 001	Jun 18, 1997	Jul	CAHN
>D>	@		30MG	A040448 001	Jan 22, 2003	Jul	CAHN
>D>	@		37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN
AA		LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
>A>	@	MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
>A>	@		30MG	A040448 001	Jan 22, 2003	Jul	CAHN
>A>	@		30MG	A040227 001	Jun 18, 1997	Jul	CAHN
>A>	@		37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>D>	@	ACTAVIS TOTOWA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
>A>	@	MIKAH PHARMA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
	@	SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD
	+		37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

>A> PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A>		QSYMIA					
>A>		VIVUS	EQ 3.75MG BASE;23MG	N022580 001	Jul 17, 2012	Jul	NEWA
>A>			EQ 7.5MG BASE;46MG	N022580 002	Jul 17, 2012	Jul	NEWA
>A>			EQ 11.25MG BASE;69MG	N022580 003	Jul 17, 2012	Jul	NEWA
>A>	+		EQ 15MG BASE;92MG	N022580 004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION					
PHENYTOIN SODIUM					
AP	+ HIKMA MAPLE	50MG/ML	A084307 001	Jun	CAHN

PHYTONADIONE

INJECTABLE; INJECTION					
PHYTONADIONE					
BP	+ INTL MEDICATION	1MG/0.5ML	A083722 001	Feb	CRLD
TABLET; ORAL					
MEPHYTON					
	+ VALEANT PHARMS	5MG	N010104 003	Jun	CAHN

PINDOLOL

TABLET; ORAL					
PINDOLOL					
	@ MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992	May CAHN
	@	10MG	A074018 001	Sep 24, 1992	May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL					
ACTOS					
	TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar CAHN
		EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar CAHN
	+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL					
K+10					
	@ FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987	Mar DISC
	KAON CL-10				
	@ SAVAGE LABS	10MEQ	N017046 002		Mar DISC
	KLOR-CON M20				
AB	+ UPSHER SMITH LABS	20MEQ	A074726 001	Nov 20, 1998	Mar CRLD
	KLOTRIX				
	@ APOTHECON	10MEQ	N017850 001		Mar DISC
	POTASSIUM CHLORIDE				
	@ NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Mar DISC
	@ SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar DISC
	@	20MEQ	N019439 001	Jun 13, 1986	Mar DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL					
POTASSIUM CITRATE					
	@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb CAHN
	@	20MEQ/PACKET	N019647 001	Oct 13, 1988	Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL					
PRAMIPEXOLE DIHYDROCHLORIDE					
AB	APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr NEWA
AB		0.25MG	A090151 002	Apr 30, 2012	Apr NEWA
AB		0.5MG	A090151 003	Apr 30, 2012	Apr NEWA
AB		0.75MG	A090151 006	Apr 30, 2012	Apr NEWA
AB		1MG	A090151 004	Apr 30, 2012	Apr NEWA

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	APOTEX INC	1.5MG	A090151 005	Apr 30, 2012	Apr	NEWA
----	------------	-------	-------------	--------------	-----	------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

@ PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006 Jun DISC

@

20MG

A077730 002 Nov 21, 2006 Jun DISC

@

30MG

A077730 003 Nov 21, 2006 Jun DISC

@

40MG

A077730 005 Nov 21, 2006 Jun DISC

@ RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007 Apr DISC

@

20MG

A076445 002 Apr 23, 2007 Apr DISC

@

40MG

A076445 003 Apr 23, 2007 Apr DISC

@

80MG

A076445 004 Apr 23, 2007 Apr DISC

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

>D>	AA	HI TECH PHARMA	15MG/5ML	A040401 001	Feb 27, 2003	Jul	CRLD
-----	----	----------------	----------	-------------	--------------	-----	------

>A>	AA	+	HI TECH PHARMA CO	15MG/5ML	A040401 001	Feb 27, 2003	Jul	CRLD
-----	----	---	-------------------	----------	-------------	--------------	-----	------

@ NESHER PHARMS

5MG/5ML

A040423 001 Oct 22, 2001 Jun DISC

@

15MG/5ML

A040364 001 Apr 10, 2002 Jun DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

>A>	+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396 001	Sep 13, 2010	Jul	CAHN
-----	---	----------------	------------------	-------------	--------------	-----	------

@ NESHER PHARMS

EQ 5MG BASE/5ML

A076982 001 May 24, 2005 Jun DISC

>D>	+	PHARM ASSOC	EQ 25MG BASE/5ML	A091396 001	Sep 13, 2010	Jul	CAHN
-----	---	-------------	------------------	-------------	--------------	-----	------

PREDNISONE

>A> TABLET, DELAYED RELEASE; ORAL

>A> RAYOS

>A>		HORIZON PHARMA	1MG	N202020 001	Jul 26, 2012	Jul	NEWA
-----	--	----------------	-----	-------------	--------------	-----	------

>A>			2MG	N202020 002	Jul 26, 2012	Jul	NEWA
-----	--	--	-----	-------------	--------------	-----	------

>A>	+		5MG	N202020 003	Jul 26, 2012	Jul	NEWA
-----	---	--	-----	-------------	--------------	-----	------

PREGABALIN

CAPSULE; ORAL

LYRICA

AB	PF PRISM	25MG	N021446 001	Dec 30, 2004	Jun	CFTG
----	----------	------	-------------	--------------	-----	------

25MG

N021446 001 Dec 30, 2004 Jan CAHN

AB		50MG	N021446 002	Dec 30, 2004	Jun	CFTG
----	--	------	-------------	--------------	-----	------

50MG

N021446 002 Dec 30, 2004 Jan CAHN

AB		75MG	N021446 003	Dec 30, 2004	Jun	CFTG
----	--	------	-------------	--------------	-----	------

75MG

N021446 003 Dec 30, 2004 Jan CAHN

100MG

N021446 004 Dec 30, 2004 Jan CAHN

CAPSULE; ORAL						
LYRICA						
AB	PF PRISM	150MG	N021446 005	Dec 30, 2004	Jun	CFTG
		150MG	N021446 005	Dec 30, 2004	Jan	CAHN
AB		200MG	N021446 006	Dec 30, 2004	Jun	CFTG
		200MG	N021446 006	Dec 30, 2004	Jan	CAHN
AB		225MG	N021446 007	Dec 30, 2004	Jun	CFTG
		225MG	N021446 007	Dec 30, 2004	Jan	CAHN
AB	+	300MG	N021446 008	Dec 30, 2004	Jun	CFTG
	+	300MG	N021446 008	Dec 30, 2004	Jan	CAHN
PREGABALIN						
AB	LUPIN LTD	25MG	A091040 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091040 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091040 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091040 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091040 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091040 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091040 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091040 008	Jul 03, 2012	Jun	NEWA
AB	TEVA PHARMS	25MG	A091219 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091219 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091224 001	Jul 03, 2012	Jun	NEWA
AB		100MG	A091224 002	Jul 03, 2012	Jun	NEWA
AB		150MG	A091224 003	Jul 03, 2012	Jun	NEWA
AB		200MG	A091224 004	Jul 03, 2012	Jun	NEWA
AB		225MG	A091224 005	Jul 03, 2012	Jun	NEWA
AB		300MG	A091224 006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG	A091221 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091221 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091221 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091221 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091221 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091221 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091221 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091221 008	Jul 03, 2012	Jun	NEWA
SOLUTION; ORAL						
LYRICA						
	+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan CAHN
<u>PRILOCAINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
CITANEST PLAIN DENTAL						
	@	DENTSPLY PHARM	4%	N021382 001		May DISC
PRILOCAINE HYDROCHLORIDE						
	+	SEPTODONT INC	4%	A079235 001	Sep 29, 2010	May CRLD
<u>PROCAINAMIDE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
PROCAINAMIDE HYDROCHLORIDE						
	@	HIKMA MAPLE	100MG/ML	A089029 001	Apr 17, 1986	Jun CAHN
	@		500MG/ML	A089030 001	Apr 17, 1986	Jun CAHN
<u>PROCHLORPERAZINE EDISYLATE</u>						
INJECTABLE; INJECTION						
PROCHLORPERAZINE EDISYLATE						
	@	HIKMA MAPLE	EQ 5MG BASE/ML	A089523 001	May 03, 1988	Jun CAHN

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	HIKMA MAPLE	EQ 5MG BASE/ML	A089903 001	Aug 29, 1989	Jun	CAHN
----	---	-------------	----------------	-------------	--------------	-----	------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB		TEVA PHARMS	100MG	A202121 001	Feb 29, 2012	Feb	NEWA
----	--	-------------	-------	-------------	--------------	-----	------

AB			200MG	A202121 002	Feb 29, 2012	Feb	NEWA
----	--	--	-------	-------------	--------------	-----	------

PROMETRIUM

AB		ABBOTT LABS	100MG	N019781 001	May 14, 1998	Feb	CFTG
----	--	-------------	-------	-------------	--------------	-----	------

AB	+		200MG	N019781 002	Oct 15, 1999	Feb	CFTG
----	---	--	-------	-------------	--------------	-----	------

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		TRIS PHARMA INC	6.25MG/5ML	A091675 001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	------------	-------------	--------------	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

	@	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Jun	DISC
--	---	---------------	-------	-------------	--------------	-----	------

	@		225MG	A076193 002	Feb 07, 2002	Jun	DISC
--	---	--	-------	-------------	--------------	-----	------

	@		300MG	A076193 003	Feb 07, 2002	Jun	DISC
--	---	--	-------	-------------	--------------	-----	------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

>D>	@	ODYSSEY PHARMS	5MG	N016012 001		Jul	CAHN
-----	---	----------------	-----	-------------	--	-----	------

>D>	@		10MG	N016012 002		Jul	CAHN
-----	---	--	------	-------------	--	-----	------

>A>	@	TEVA WOMENS R AND D	5MG	N016012 001		Jul	CAHN
-----	---	---------------------	-----	-------------	--	-----	------

>A>	@		10MG	N016012 002		Jul	CAHN
-----	---	--	------	-------------	--	-----	------

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	60MG	N009829 002		Jun	CAHN
----	---	--------------------	------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MESTINON

	+	VALEANT PHARMS LLC	180MG	N011665 001		Jun	CAHN
--	---	--------------------	-------	-------------	--	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
----	--	---------------------	--------------	-------------	--------------	-----	------

AB			EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

AB			EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB		APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
----	--	------------	--------------	-------------	--------------	-----	------

AB			EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

AB			EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

TABLET; ORAL

QUETIAPINE FUMARATE

AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA
SEROQUEL						
AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

RAMELTEON

TABLET; ORAL

ROZEREM

>D>	+	TAKEDA GLOBAL	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
>A>	+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009 Apr DISC

@

10MG

A078849 002 Mar 06, 2009 Apr DISC

TABLET; ORAL

ALTACE

@ KING PFIZER

1.25MG

N022021 001 Feb 27, 2007 Jan DISC

@

2.5MG

N022021 002 Feb 27, 2007 Jan DISC

@

5MG

N022021 003 Feb 27, 2007 Jan DISC

@

10MG

N022021 004 Feb 27, 2007 Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP + COVIS PHARMA EQ 25MG BASE/ML

N019090 001 Oct 19, 1984 Mar CAHN

ZANTAC IN PLASTIC CONTAINER

+ COVIS PHARMA EQ 1MG BASE/ML

N019593 002 Sep 27, 1991 Mar CAHN

@

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986 Mar CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB PROSAM LABS 300MG

N050429 001 Feb CMFD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+ JANSSEN PRODS EQ 25MG BASE

N202022 001 May 20, 2011 Feb CAHN

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB WARNER CHILCOTT LLC 5MG

N020835 002 Apr 14, 2000 Jun CAHN

AB 30MG

N020835 001 Mar 27, 1998 Jun CAHN

AB + 35MG

N020835 003 May 25, 2002 Jun CAHN

@

75MG

N020835 004 Apr 16, 2007 Jun CAHN

+ 150MG

N020835 005 Apr 22, 2008 Jun CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+ WARNER CHILCOTT LLC 35MG

N022560 001 Oct 08, 2010 Jun CAHN

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB PROSAM LABS 0.25MG

A078071 001 Jun 17, 2009 Feb CMFD

AB 0.5MG

A078071 002 Jun 17, 2009 Feb CMFD

AB 1MG

A078071 003 Jun 17, 2009 Feb CMFD

AB 2MG

A078071 004 Jun 17, 2009 Feb CMFD

TABLET; ORAL						
RISPERIDONE						
AB	PROSAM LABS	3MG	A078071	005	Jun 17, 2009	Feb CMFD
AB		4MG	A078071	006	Jun 17, 2009	Feb CMFD
TABLET, ORALLY DISINTEGRATING; ORAL						
RISPERIDONE						
AB	TEVA	0.5MG	A076908	001	Mar 12, 2012	Feb NEWA
AB		1MG	A076908	002	Mar 12, 2012	Feb NEWA
AB		2MG	A076908	003	Mar 12, 2012	Feb NEWA
<u>RIVASTIGMINE TARTRATE</u>						
CAPSULE; ORAL						
RIVASTIGMINE TARTRATE						
AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689	001	Jun 12, 2012	May NEWA
AB		EQ 3MG BASE	A091689	002	Jun 12, 2012	May NEWA
AB		EQ 4.5MG BASE	A091689	003	Jun 12, 2012	May NEWA
AB		EQ 6MG BASE	A091689	004	Jun 12, 2012	May NEWA
<u>ROPINIROLE HYDROCHLORIDE</u>						
TABLET; ORAL						
ROPINIROLE HYDROCHLORIDE						
AB	APOTEX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Jan NEWA
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Jan NEWA
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Jan NEWA
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Jan NEWA
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Jan NEWA
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Jan NEWA
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Jan NEWA
TABLET, EXTENDED RELEASE; ORAL						
REQUIP XL						
AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008	001	Jun 13, 2008	Apr CFTG
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008	Apr CFTG
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009	Apr CFTG
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008	Apr CFTG
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008	Apr CFTG
ROPINIROLE HYDROCHLORIDE						
AB	ACTAVIS	EQ 2MG BASE	A090869	001	May 17, 2012	Apr NEWA
AB		EQ 4MG BASE	A090869	002	May 17, 2012	Apr NEWA
AB		EQ 6MG BASE	A090869	003	May 17, 2012	Apr NEWA
AB		EQ 8MG BASE	A090869	004	May 17, 2012	Apr NEWA
AB		EQ 12MG BASE	A090869	005	May 17, 2012	Apr NEWA
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012	May NEWA
AB		EQ 4MG BASE	A201576	002	Jun 06, 2012	May NEWA
AB		EQ 6MG BASE	A201576	003	Jun 06, 2012	May NEWA
AB		EQ 8MG BASE	A201576	004	Jun 06, 2012	May NEWA
AB		EQ 12MG BASE	A201576	005	Jun 06, 2012	May NEWA
AB	SANDOZ INC	EQ 2MG BASE	A201047	001	Jun 06, 2012	May NEWA
AB		EQ 4MG BASE	A201047	003	Jun 06, 2012	May NEWA
AB		EQ 6MG BASE	A201047	004	Jun 06, 2012	May NEWA
AB		EQ 8MG BASE	A201047	005	Jun 06, 2012	May NEWA
AB		EQ 12MG BASE	A201047	006	Jun 06, 2012	May NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	May NEWA
AB		EQ 4MG BASE	A200431	002	Jun 06, 2012	May NEWA
AB		EQ 6MG BASE	A200431	003	Jun 06, 2012	May NEWA
AB		EQ 8MG BASE	A200431	004	Jun 06, 2012	May NEWA
AB		EQ 12MG BASE	A200431	005	Jun 06, 2012	May NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC

1MG/24HR

N021829 004 Apr 02, 2012 Apr NEWA

2MG/24HR

N021829 001 May 09, 2007 Apr CMFD

3MG/24HR

N021829 005 Apr 02, 2012 Apr NEWA

4MG/24HR

N021829 002 May 09, 2007 Apr CMFD

6MG/24HR

N021829 003 May 09, 2007 Apr CMFD

+

8MG/24HR

N021829 006 Apr 02, 2012 Apr NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

>D>

+

EUSA PHARMA USA

50mCi/ML

N020570 001 Mar 28, 1997 Jul CAHN

>A>

+

JAZZ EUSA PHARMA

50mCi/ML

N020570 001 Mar 28, 1997 Jul CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+

VALEANT INTL

2%

N021385 001 Dec 10, 2003 Jan CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB

PROSAM LABS

EQ 25MG BASE

A078175 001 Jul 21, 2010 Feb CMFD

AB

EQ 50MG BASE

A078175 002 Jul 21, 2010 Feb CMFD

AB

EQ 100MG BASE

A078175 003 Jul 21, 2010 Feb CMFD

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB

THEPHARMANETWORK LLC 1%

N018810 001 Dec 23, 1985 Jun CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB

PROSAM LABS

5MG

A078735 001 Aug 30, 2010 Feb CMFD

AB

10MG

A078735 002 Aug 30, 2010 Feb CMFD

AB

20MG

A078735 003 Aug 30, 2010 Feb CMFD

AB

40MG

A078735 004 Aug 30, 2010 Feb CMFD

AB

80MG

A078735 005 Aug 30, 2010 Feb CMFD

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK SHARP DOHME

EQ 25MG BASE

N021995 001 Oct 16, 2006 May CAHN

EQ 50MG BASE

N021995 002 Oct 16, 2006 May CAHN

+

EQ 100MG BASE

N021995 003 Oct 16, 2006 May CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985 Jan CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

@ BRACCO	200uCi/ML	N013993 001		Jun	DISC
----------	-----------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
-----------------	--------	-------------	--	-----	------

SOLUTION; ORAL

SODIUM IODIDE I 123

>D>	+ GE HEALTHCARE	2mCi/ML	N017630 002		Jul	DISC
-----	-----------------	---------	-------------	--	-----	------

>A>	@	2mCi/ML	N017630 002		Jul	DISC
-----	---	---------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE	9-100mCi	N021305 006	May 19, 2005	Feb	CAHN
--------------------	----------	-------------	--------------	-----	------

@	2-200mCi	N021305 004	Nov 18, 2004	Jan	DISC
---	----------	-------------	--------------	-----	------

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE	1-500mCi/0.5ML	N021305 003	Jan 24, 2003	Feb	DISC
----------------------	----------------	-------------	--------------	-----	------

@	1-250mCi/0.25ML	N021305 002	Jan 24, 2003	Feb	DISC
---	-----------------	-------------	--------------	-----	------

@	1-1000mCi/ML	N021305 005	Apr 04, 2006	Feb	DISC
---	--------------	-------------	--------------	-----	------

+	250-1000mCi	N021305 007	Dec 05, 2011	Jan	NEWA
---	-------------	-------------	--------------	-----	------

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922 001	Feb 14, 2012	Feb	NEWA
---	-------------	----------------------	-------------	--------------	-----	------

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+	JAZZ PHARMS	500MG/ML	N021196 001	Jul 17, 2002	Jun	CAHN
---	-------------	----------	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHARMA	454GM/BOT	A040909 001	Dec 03, 2008	Jun	DISC
----------------	-----------	-------------	--------------	-----	------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923 001	Feb 14, 2012	Feb	NEWA
---	-------------	------------------------	-------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

>D>		NORDITROPIN				
>D>	BX	NOVO NORDISK INC	5MG/1.5ML	N021148 001	Jun 20, 2000	Jul DISC
>A>		@	5MG/1.5ML	N021148 001	Jun 20, 2000	Jul DISC
>D>	BX		10MG/1.5ML	N021148 002	Jun 20, 2000	Jul DISC
>A>		@	10MG/1.5ML	N021148 002	Jun 20, 2000	Jul DISC
>D>		+	15MG/1.5ML	N021148 003	Jun 20, 2000	Jul DISC
>A>		@	15MG/1.5ML	N021148 003	Jun 20, 2000	Jul DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2	EPIC PHARMA INC	80MG	A077070 001	Nov 04, 2005	Jun	CAHN
AB2		120MG	A077070 002	Nov 04, 2005	Jun	CAHN
AB2		160MG	A077070 003	Nov 04, 2005	Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	N022408 001	Jan 18, 2011	May	CAHN
---	-------------	------	-------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK LLC	100MG	N019998 002	Jan 30, 1991	Mar	CAHN
---	--------------	-------	-------------	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	-------------	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

	+	JAZZ PHARMS COMMERCL	15%	N006530 003	Jan 27, 1987	Mar CAHN
>A>	+	JAZZ PHARMS II	15%	N006530 003	Jan 27, 1987	Jul CAHN
>D>	+	JAZZ PHARMS III	15%	N006530 003	Jan 27, 1987	Jul CAHN
	+		15%	N006530 003	Jan 27, 1987	Jun CAHN

SUPPOSITORY; VAGINAL

AVC

	@	JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar CAHN
>A>	@	JAZZ PHARMS II	1.05GM	N006530 004	Jan 27, 1987	Jul CAHN
>D>	@	JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jul CAHN
	@		1.05GM	N006530 004	Jan 27, 1987	Jun CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD
----	----------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN
----	------------	-------------------------------------	-------------	--------------	-----	------

SUMAVEL DOSEPRO

BX	+ ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC
----	---------------	-------------------------------------	-------------	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263 001	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE	A200263 002	Jun 19, 2012	Jun	NEWA
AB		EQ 100MG BASE	A200263 003	Jun 19, 2012	Jun	NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

@	AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
---	--------------	--------------	-------------	--------------	-----	------

@		EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC
---	--	--------------	-------------	--------------	-----	------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@	JUBILANT DRAXIMAGE	N/A	N018035 001		May	CAHN
---	--------------------	-----	-------------	--	-----	------

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--------------------	-----	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA
----	--	--------	-------------	--------------	-----	------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
----	-------------------	-----	-------------	--------------	-----	------

AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
----	--	------	-------------	--------------	-----	------

CAPSULE; ORAL						
TEMODAR						
AB	MERCK SHARP DOHME	100MG	N021029 003	Aug 11, 1999	Jun	CAHN
AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN
POWDER; INTRAVENOUS						
TEMODAR						
+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
<u>TENOFOVIR DISOPROXIL FUMARATE</u>						
POWDER; ORAL						
VIREAD						
+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012	Jan	NEWA
TABLET; ORAL						
VIREAD						
	GILEAD SCIENCES INC	150MG	N021356 002	Jan 18, 2012	Apr	NEWA
		200MG	N021356 003	Jan 18, 2012	Apr	NEWA
		250MG	N021356 004	Jan 18, 2012	Apr	NEWA
<u>TERAZOSIN HYDROCHLORIDE</u>						
CAPSULE; ORAL						
TERAZOSIN HYDROCHLORIDE						
	@ RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002	Apr	DISC
	@	EQ 2MG BASE	A076021 002	Aug 22, 2002	Apr	DISC
	@	EQ 5MG BASE	A076021 003	Aug 22, 2002	Apr	DISC
	@	EQ 10MG BASE	A076021 004	Aug 22, 2002	Apr	DISC
<u>TERBUTALINE SULFATE</u>						
INJECTABLE; INJECTION						
TERBUTALINE SULFATE						
	@ TEVA PARENTERAL	1MG/ML	A076853 001	Jul 20, 2004	Jan	DISC
<u>TERCONAZOLE</u>						
CREAM; VAGINAL						
TERCONAZOLE						
AB	FOUGERA PHARMS	0.4%	A076712 001	Feb 18, 2005	Jan	CAHN
SUPPOSITORY; VAGINAL						
TERCONAZOLE						
AB	FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006	Jan	CAHN
<u>TESAMORELIN ACETATE</u>						
POWDER; SUBCUTANEOUS						
EGRIFTA						
	@ EMD SERONO	EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	Jun	DISC
+		EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	May	CAHN
+		EQ 2MG BASE/VIAL	N022505 002	Nov 29, 2011	Jun	NEWA
<u>TESTOSTERONE</u>						
GEL; TRANSDERMAL						
ANDROGEL						
BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb CPOT
			1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb CPOT
TESTIM						
BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454 001	Oct 31, 2002	Feb CPOT

GEL; TRANSDERMAL									
TESTOSTERONE									
	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA		
		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Feb	NEWA		
GEL, METERED; TRANSDERMAL									
ANDROGEL									
+	ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015	003	Sep 26, 2003	Jun	CPOT		
PELLET; IMPLANTATION									
TESTOPEL									
+	ACTIENT PHARMS	75MG	A080911	001		May	CAHN		
<u>TESTOSTERONE CYPIONATE</u>									
INJECTABLE; INJECTION									
TESTOSTERONE CYPIONATE									
AO	HIKMA FARMACEUTICA	200MG/ML	A091244	001	May 01, 2012	Apr	NEWA		
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Feb	CAHN		
<u>TESTOSTERONE ENANTHATE</u>									
INJECTABLE; INJECTION									
TESTOSTERONE ENANTHATE									
AO	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Feb	CAHN		
<u>TETRABENAZINE</u>									
TABLET; ORAL									
XENAZINE									
	VALEANT PHARMS	12.5MG	N021894	001	Aug 15, 2008	Apr	CAHN		
+		25MG	N021894	002	Aug 15, 2008	Apr	CAHN		
<u>TETRAHYDROZOLINE HYDROCHLORIDE</u>									
SOLUTION; NASAL									
TYZINE									
+	FOUGERA PHARMS	0.05%	A086576	002		Jan	CAHN		
		0.1%	A086576	001		Jan	CAHN		
SPRAY; NASAL									
TYZINE									
+	FOUGERA PHARMS	0.1%	A086576	003		Jan	CAHN		
<u>THEOPHYLLINE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
THEO-24									
	UCB INC	100MG	A087942	001	Aug 22, 1983	May	CTEC		
		200MG	A087943	001	Aug 22, 1983	May	CTEC		
		300MG	A087944	001	Aug 22, 1983	May	CTEC		
+		400MG	A081034	001	Feb 28, 1992	May	CRLD		
THEOPHYLLINE									
@	INWOOD LABS	100MG	A040052	001	Feb 14, 1994	May	DISC		
@		125MG	A040052	002	Feb 14, 1994	May	DISC		
@		200MG	A040052	003	Feb 14, 1994	May	DISC		
@		300MG	A040052	004	Feb 14, 1994	May	DISC		
INJECTABLE; INJECTION									
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER									
@	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC		
@		40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC		
@		80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC		
@		160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC		
@		200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC		

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

320MG/100ML

N018649 006 Nov 13, 1985 Mar DISC

@

400MG/100ML

N018649 005 Jul 26, 1982 Mar DISC

SOLUTION; ORAL

THEOPHYLLINE

AA + SILARX

80MG/15ML

A091156 001 Apr 13, 2011 Jun CTEC

AA TRIS PHARMA INC

80MG/15ML

A091586 001 Jun 15, 2012 Jun NEWA

TABLET; ORAL

THEOLAIR

>D> + GRACEWAY

125MG

A086399 001 Jul CAHN

>D> +

250MG

A086399 002 Jul CAHN

>A> + MEDICIS

125MG

A086399 001 Jul CAHN

>A> +

250MG

A086399 002 Jul CAHN

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP MYLAN INSTITUTIONAL

100MG/ML

A091623 001 Jun 25, 2012 Jun NEWA

TIAGABINE HYDROCHLORIDETABLET; ORAL

GABITRIL

@ CEPHALON

6MG

N020646 006 Nov 29, 2005 Jan DISC

@

8MG

N020646 007 Nov 29, 2005 Jan DISC

@

10MG

N020646 008 Nov 29, 2005 Jan DISC

TINIDAZOLETABLET; ORAL

TINDAMAX

AB MISSION PHARMA

250MG

N021618 001 May 17, 2004 Apr CFTG

AB +

500MG

N021618 002 May 17, 2004 Apr CFTG

TINIDAZOLE

AB NOVEL LABS INC

250MG

A202044 001 Apr 30, 2012 Apr NEWA

AB

500MG

A202044 002 Apr 30, 2012 Apr NEWA

AB ROXANE

250MG

A201172 001 Apr 30, 2012 Apr NEWA

AB

500MG

A201172 002 Apr 30, 2012 Apr NEWA

TINZAPARIN SODIUMINJECTABLE; INJECTION

INNOHEP

@ LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000 Jun DISC

TIZANIDINE HYDROCHLORIDECAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB APOTEX INC

EQ 2MG BASE

A078868 001 Feb 03, 2012 Jan NEWA

AB

EQ 4MG BASE

A078868 002 Feb 03, 2012 Jan NEWA

AB

EQ 6MG BASE

A078868 003 Feb 03, 2012 Jan NEWA

ZANAFLEX

AB ACORDA

EQ 2MG BASE

N021447 001 Aug 29, 2002 Jan CFTG

AB

EQ 4MG BASE

N021447 002 Aug 29, 2002 Jan CFTG

AB +

EQ 6MG BASE

N021447 003 Aug 29, 2002 Jan CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB PROSAM LABS

EQ 2MG BASE

A076281 001 Oct 20, 2003 Feb CMFD

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
	@ WATSON LABS	500MG	A086109 001		Mar	DISC
	@	500MG	A087318 001		Mar	DISC

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
	@	200MG	N020697 002	Jan 29, 1998	May	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

>A>	AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
-----	----	----------------	------------------	-------------	--------------	-----	------

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS	100MG	A091609 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A091609 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A091609 003	Jun 27, 2012	Jun	NEWA
AB2	ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A200491 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A200491 003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRETINOIN

CREAM; TOPICAL

AVITA

AB	MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997	Jun	CAHN
----	------------------	--------	-------------	--------------	-----	------

RENOVA

+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
AB2	+	0.05%	N019963 001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
----	---	--------------	--------	-------------	--------------	-----	------

CREAM; TOPICAL									
RETIN-A									
AB1	+	VALEANT INTL	0.05%	N017522	001		Jan	CAHN	
AB	+		0.1%	N017340	001		Jan	CAHN	
TRETINOIN									
AB		PRECISION DERMAT	0.025%	A075264	001	Dec 24, 1998	May	CAHN	
	+		0.0375%	A090098	001	Mar 22, 2010	May	CAHN	
AB1			0.05%	A075265	001	Dec 24, 1998	May	CAHN	
AB			0.1%	A075213	001	Dec 24, 1998	May	CAHN	
AB2		SUNEVA MEDCL	0.05%	A076498	001	Sep 15, 2005	May	CAHN	
GEL; TOPICAL									
RETIN-A									
AB	+	VALEANT INTL	0.01%	N017955	001		Jan	CAHN	
AB	+		0.025%	N017579	002		Jan	CAHN	
TRETINOIN									
AB		PRECISION DERMAT	0.01%	A075589	001	Jun 11, 2002	May	CAHN	
AB			0.025%	A075529	001	Feb 22, 2000	May	CAHN	
SOLUTION; TOPICAL									
RETIN-A									
AT	+	VALEANT INTL	0.05%	N016921	001		Jan	CAHN	
SWAB; TOPICAL									
RETIN-A									
	@	VALEANT INTL	0.05%	N016921	002		Jan	CAHN	
<u>TRIAMCINOLONE ACETONIDE</u>									
AEROSOL, METERED; INHALATION									
AZMACORT									
	@	ABBOTT	0.1MG/INH	N018117	001	Apr 23, 1982	May	DISC	
CREAM; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%	A085692	001		Jan	CAHN	
AT			0.1%	A085692	003		Jan	CAHN	
AT	+		0.5%	A085692	002		Jan	CAHN	
LOTION; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003	Jan	CAHN	
AT			0.1%	A040467	002	Apr 21, 2003	Jan	CAHN	
OINTMENT; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%	A085691	001		Jan	CAHN	
AT			0.1%	A085691	003		Jan	CAHN	
AT			0.5%	A085691	002		Jan	CAHN	
SPRAY, METERED; NASAL									
TRIAMCINOLONE ACETONIDE									
AB		TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN	
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
TRIMETHOBENZAMIDE HYDROCHLORIDE									
	@	HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987	Jun	DISC	
<u>VALACYCLOVIR HYDROCHLORIDE</u>									
TABLET; ORAL									
VALACYCLOVIR HYDROCHLORIDE									
AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA	
AB			EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA	

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May	CAHN
---	-------------------	---------	-------------	--------------	-----	------

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May	CAHN
---	-------------------	---------------	-------------	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
----	------------	---------------	-------------	--------------	-----	------

AB	+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG
----	---	---------------	-------------	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
----	-------	---------------	-------------	--------------	-----	------

AB		EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
----	--	---------------	-------------	--------------	-----	------

AB	APP PHARMS LLC	EQ 125MG BASE	A065453 001	Jun 18, 2012	Jun	NEWA
----	----------------	---------------	-------------	--------------	-----	------

AB		EQ 250MG BASE	A065453 002	Jun 18, 2012	Jun	NEWA
----	--	---------------	-------------	--------------	-----	------

AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
----	---------------------	---------------	-------------	--------------	-----	------

AB		EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
----	--	---------------	-------------	--------------	-----	------

AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
----	-------------	---------------	-------------	--------------	-----	------

AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA
----	--	---------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>A>	AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837 001	Aug 10, 2012	Jul	NEWA
-----	----	---------------	------------------	-------------	--------------	-----	------

>A>	AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048 001	Aug 10, 2012	Jul	NEWA
-----	----	------------	------------------	-------------	--------------	-----	------

>A>	AP		EQ 10GM BASE/VIAL	A201048 002	Aug 10, 2012	Jul	NEWA
-----	----	--	-------------------	-------------	--------------	-----	------

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
--	----------------	-------	-------------	--------------	-----	------

+		300MG	N022405 002	Apr 06, 2011	Feb	CTNA
---	--	-------	-------------	--------------	-----	------

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
----	----------------	-------	-------------	--------------	-----	------

AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
----	--	-----	-------------	--------------	-----	------

AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
----	--	------	-------------	--------------	-----	------

AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG
----	---	------	-------------	--------------	-----	------

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
----	-------------	-------	-------------	--------------	-----	------

AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
----	--	-----	-------------	--------------	-----	------

AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
----	--	------	-------------	--------------	-----	------

AB		20MG	A091347 004	May 03, 2012	Apr	NEWA
----	--	------	-------------	--------------	-----	------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
----	---------	-----------	-------------	--------------	-----	------

		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
--	--	-----------	-------------	--------------	-----	------

AP	+	SUN PHARMA GLOBAL	10MG/VIAL	A079001 001	Jun 17, 2009	Jun	CRLD
----	---	-------------------	-----------	-------------	--------------	-----	------

AP	+		20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD
----	---	--	-----------	-------------	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB		APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB			180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB			240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
		40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267 001	May 24, 2002	May	CFTG
----	---	--------	------------	-------------	--------------	-----	------

VORICONAZOLE

AP		SANDOZ INC	200MG/VIAL	A090862 001	May 30, 2012	May	NEWA
----	--	------------	------------	-------------	--------------	-----	------

TABLET; ORAL

VORICONAZOLE

AB		TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	Mar	NEWA
AB			200MG	A091658 002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN
---	----------------------	------------------------	-------------	--------------	-----	------

@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Jun	CAHN
---	------------------	------------------------	-------------	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Jun	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Jun	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

@	RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005	Apr	DISC
---	------------------	-------	---------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825	002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825	003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825	004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561	004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565	004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560	004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562	001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562	002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562	003	Jun 01, 2012	May	NEWA
AB			EQ 80MG BASE	A077562	004	Jun 01, 2012	May	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

>A>	AB	CIPLA LTD	5MG	A077388	001	Jul 30, 2012	Jul	NEWA
>A>	AB		10MG	A077388	002	Jul 30, 2012	Jul	NEWA

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958 001	Oct 16, 2000	Mar	CAHN
---	-------------	------------------	-------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	RANBAXY	5MG/5ML	A090183 002	Apr 24, 2008	Jul	DISC
-----	---------	---------	-------------	--------------	-----	------

>A>	@ RANBAXY LABS LTD	5MG/5ML	A090183 002	Apr 24, 2008	Jul	DISC
-----	--------------------	---------	-------------	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>	RANBAXY	5MG/5ML	A090183 001	Apr 24, 2008	Jul	DISC
-----	---------	---------	-------------	--------------	-----	------

>A>	@ RANBAXY LABS LTD	5MG/5ML	A090183 001	Apr 24, 2008	Jul	DISC
-----	--------------------	---------	-------------	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCRUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	-------------	--------------	-----	------

CHLORASCRUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Mar	CAHN
---	------------	-----------------	-------------	--------------	-----	------

CHLORASCRUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	-------------	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

	TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135 001	May 25, 2012	May	NEWA
--	-----------------	-----------------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888 001	Mar 05, 2012	Feb	NEWA
--	---------------------	--	-------------	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@	MCNEIL CONS	10MG	N020801 001	Sep 24, 1998	Mar	CAHN
---	-------------	------	-------------	--------------	-----	------

+		20MG	N020801 002	Dec 17, 2007	Mar	CAHN
---	--	------	-------------	--------------	-----	------

TABLET; ORAL

PEPCID AC

	MCNEIL CONS	10MG	N020325 001	Apr 28, 1995	Mar	CAHN
--	-------------	------	-------------	--------------	-----	------

+		20MG	N020325 002	Sep 23, 2003	Mar	CAHN
---	--	------	-------------	--------------	-----	------

PEPCID AC (GELTAB)

	MCNEIL CONS	10MG	N020902 001	Aug 05, 1999	Mar	CAHN
--	-------------	------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	SUN PHARM INDS	30MG	A091567 002	Feb 06, 2012	Jan	NEWA
--	----------------	------	-------------	--------------	-----	------

	WOCKHARDT LTD	30MG	A079112 002	Feb 08, 2012	Jan	NEWA
--	---------------	------	-------------	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	SUN PHARM INDS	30MG	A091567 001	Feb 06, 2012	Jan	NEWA
--	----------------	------	-------------	--------------	-----	------

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

WOCKHARDT LTD	30MG	A079112 001	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	60MG	A091567 004	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

	180MG	A091567 006	Feb 06, 2012	Jan	NEWA
--	-------	-------------	--------------	-----	------

WOCKHARDT LTD	60MG	A079112 004	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

	180MG	A079112 006	Feb 08, 2012	Jan	NEWA
--	-------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567 003	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

	180MG	A091567 005	Feb 06, 2012	Jan	NEWA
--	-------	-------------	--------------	-----	------

WOCKHARDT LTD	60MG	A079112 003	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

	180MG	A079112 005	Feb 08, 2012	Jan	NEWA
--	-------	-------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338 001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	-------------	--------------	-----	------

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803 001	Jun 12, 2012	Jun	NEWA
------------------------	---------------	-------------	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194 001	May 18, 2012	Apr	NEWA
--------------------	------	-------------	--------------	-----	------

PERRIGO R AND D	15MG	A202319 001	May 18, 2012	Apr	NEWA
-----------------	------	-------------	--------------	-----	------

WOCKHARDT LTD	15MG	A202727 001	May 18, 2012	Apr	NEWA
---------------	------	-------------	--------------	-----	------

PREVACID 24 HR

+ NOVARTIS	15MG	N022327 001	May 18, 2009	Apr	CFTG
------------	------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA
-----------------	-------	-------------	--------------	-----	------

PLAN B

+ TEVA BRANDED PHARM	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
----------------------	--------	-------------	--------------	-----	------

PLAN B ONE-STEP

+ DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG
-----------	-------	-------------	--------------	-----	------

LORATADINE

SYRUP; ORAL

LORATADINE

>D>	RANBAXY	1MG/ML	A076529 001	Aug 20, 2004	Jul	DISC
-----	---------	--------	-------------	--------------	-----	------

>A>	@ RANBAXY LABS LTD	1MG/ML	A076529 001	Aug 20, 2004	Jul	DISC
-----	--------------------	--------	-------------	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

AVEVA	7MG/24HR	A074612 002	Jul 28, 2003	Apr	NEWA
-------	----------	-------------	--------------	-----	------

	14MG/24HR	A074612 003	Oct 20, 1997	Apr	NEWA
--	-----------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE
SHASUN CHEMS	EQ 75MG BASE

A200172	001	May 31, 2012	May	NEWA
A201745	001	Feb 29, 2012	Feb	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2012

NO JULY 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYL CYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACCLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001					>A> NCE	Jul 23, 2017
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	RE42462	Jul 29, 2018	DS			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>AVANAFIL - STENDRA</u>									
N202276 002	6656935	Sep 13, 2020	DS DP U-155				NCE	Apr 27, 2017	
<u>AVANAFIL - STENDRA</u>									
N202276 003	6656935	Sep 13, 2020	DS DP U-155				NCE	Apr 27, 2017	
<u>AXITINIB - INLYTA</u>									
N202324 001	6534524	Jun 30, 2020	DS DP				NCE	Jan 27, 2017	
	7141581	Jun 30, 2020	U-1220						
<u>AXITINIB - INLYTA</u>									
N202324 002	6534524	Jun 30, 2020	DS DP				NCE	Jan 27, 2017	
	7141581	Jun 30, 2020	U-1220						
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>									
N202236 001	8163723	Aug 29, 2023	U-81				NC	May 01, 2015	
	8163723	Aug 29, 2023	U-77						
	8163723	Aug 29, 2023	U-707						
	8163723	Aug 29, 2023	U-644						
	8168620	Feb 24, 2026	DP						
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>									
N202331 001	5583141	Dec 10, 2013	DS DP U-3						
	5736555	Jun 25, 2012	DS DP U-3						
	7157584	May 22, 2025	DS						
	7572920	Jan 07, 2025	DP U-3						
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>									
N202331 002	5583141	Dec 10, 2013	DS DP U-3						
	5736555	Jun 25, 2012	DS DP U-3						
	7157584	May 22, 2025	DS						
	7572920	Jan 07, 2025	DP U-3						
<u>BALSALAZIDE DISODIUM - GIAZO</u>									
N022205 001	6197341	Mar 13, 2018	DP U-1229				NDF	Feb 03, 2015	
	7452872	Aug 24, 2026	U-1229						
	7625884	Aug 24, 2026	U-1229						
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>									
N202813 001	5605674	Feb 25, 2014	DP				NP	Mar 23, 2015	
	5683677	Nov 04, 2014	DP						
	5776432	Jul 07, 2015	DP						
	7780038	Jan 24, 2027	DP						
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>									
N022249 001							NCE	Mar 20, 2013	
							ODE	Mar 20, 2015	
							PED	Sep 20, 2015	
							PED	Sep 20, 2013	
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>									
N022249 002							NCE	Mar 20, 2013	
							ODE	Mar 20, 2015	
							PED	Sep 20, 2015	
							PED	Sep 20, 2013	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	>A> 7232818	Apr 14, 2025	DS DP		>A> NCE	Jul 20, 2017
	>A> 7417042	Jun 07, 2026	DS DP			
	>A> 7491704	Apr 14, 2025	U-1260			
	>A> 7737112	Dec 07, 2027	DP			
	>A> 8129346	Dec 25, 2026	U-1260			
	>A> 8207125	Apr 14, 2025	DS DP			
	>A> 8207126	Apr 14, 2025	DP			
	>A> 8207127	Apr 14, 2025	U-1260			
	>A> 8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	>A> 8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					>A> NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COLCHICINE - COLCRY</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	>A> 8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	>A> 8217057	Nov 06, 2029	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	>A> 8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	>A> 5223510	Jul 26, 2012	DS DP U-992			
	>A> 5223510	Jul 26, 2012	DS DP U-1261			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	>A> 5922695	Jul 25, 2017	DS U-1259			
	>A> 5922695	Jul 25, 2017	DS U-248			
	>A> 5922695	Jul 25, 2017	DS U-541			
	>A> 5922695	Jul 25, 2017	DS U-1170			
	>A> 5935946	Jul 25, 2017	DS DP U-541			
	>A> 5935946	Jul 25, 2017	DS DP U-1170			
	>A> 5935946	Jul 25, 2017	DS DP U-1259			
	>A> 5935946	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-1259			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-541			
	>A> 5977089	Jul 25, 2017	DS DP U-1170			
	>A> 6043230	Jul 25, 2017	DP U-541			
	>A> 6043230	Jul 25, 2017	DP U-1170			
	>A> 6043230	Jul 25, 2017	DP U-1259			
	>A> 6043230	Jul 25, 2017	DP U-248			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	>A> 5690960	Nov 25, 2014	DP U-1207			
	>A> 5690960*PED	May 25, 2015				
	>A> 5714504	Feb 03, 2015	DP U-1207			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5877192	May 27, 2014	U-1207			
	>A> 5877192*PED	Nov 27, 2014				
	>A> 5900424	May 04, 2016	DS U-1207			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1207			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1207			
	>A> 6428810*PED	May 03, 2020				
	>A> 6875872	May 27, 2014	DS			
	>A> 6875872*PED	Nov 27, 2014				
	>A> 7411070	May 25, 2018	DS			
	>A> 7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	>A> 5690960	Nov 25, 2014	DP U-1207			
	>A> 5690960*PED	May 25, 2015				
	>A> 5714504	Feb 03, 2015	DP U-1207			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5877192	May 27, 2014	U-1207			
	>A> 5877192*PED	Nov 27, 2014				
	>A> 5900424	May 04, 2016	DS U-1207			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1207			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1207			
	>A> 6428810*PED	May 03, 2020				
	>A> 6875872	May 27, 2014	DS			
	>A> 6875872*PED	Nov 27, 2014				
	>A> 7411070	May 25, 2018	DS			
	>A> 7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
N022334 002	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
N022334 003	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004					M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	>A> 8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	>A> 8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLORBETAPIR F-18 - AMYVID</u>						
N020008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	>A> 8232264	Mar 09, 2023	DP			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVISt</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	>A> 8188146	Jan 27, 2020	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	>A> 8236816	Dec 11, 2029	U-68			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	>A> 8222270	Dec 11, 2029	U-68			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	>A> 5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	>A> 8008338*PED	Nov 24, 2027				
	>A> 8207215	May 28, 2024	U-1251			
	>A> 8207215*PED	Nov 28, 2024				
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					>A> NPP	Dec 16, 2014
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					>A> NPP	Dec 16, 2014
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 003					>A> NPP	Dec 16, 2014
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 004					>A> NPP	Dec 16, 2014
<u>LEVETIRACETAM - KEPPRA</u>						
N021505 001					>A> NPP	Dec 16, 2014
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	>A> 6465709	Jul 07, 2020	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	8119648	Aug 12, 2023	U-774			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	>A> 6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	>A> 6953787	Apr 10, 2023	DS DP U-1254			
	>A> 6953787	Apr 10, 2023	DS DP U-1255			
	>A> 6953787	Apr 10, 2023	DS DP U-1252			
	>A> 7514422	Apr 10, 2023	U-1255			
	>A> 7514422	Apr 10, 2023	U-1252			
	>A> 7514422	Apr 10, 2023	U-1253			
	>A> 7514422	Apr 10, 2023	U-1254			
	>A> 7977329	Apr 10, 2023	DS DP U-1253			
	>A> 7977329	Apr 10, 2023	DS DP U-1254			
	>A> 7977329	Apr 10, 2023	DS DP U-1255			
	>A> 7977329	Apr 10, 2023	DS DP U-1252			
	>A> 8168624	Apr 18, 2029	DS DP			
	>A> 8207158	Apr 10, 2023	U-1255			
	>A> 8207158	Apr 10, 2023	U-1252			
	>A> 8207158	Apr 10, 2023	U-1253			
	>A> 8207158	Apr 10, 2023	U-1254			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002					M-116	May 17, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	>A> 6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	>A> 6562375	Aug 01, 2020	DP			
	>A> 6699503	Sep 10, 2013	DP			
	>A> 7342117	Nov 04, 2023	DS			
	>A> 7750029	Dec 18, 2023		U-913		
	>A> 7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	>A> 6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	>A> 6562375	Aug 01, 2020	DP			
	>A> 6699503	Sep 10, 2013	DP			
	>A> 7342117	Nov 04, 2023	DS			
	>A> 7750029	Dec 18, 2023		U-913		
	>A> 7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	8158156	Jun 19, 2027	U-1241			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725	004				I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175	001				NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175	002				NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222	002				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222	003				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542	002				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	005				NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	006				NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465	001	8114885	Dec 19, 2021	DS DP	I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465	002	8114885	Dec 19, 2021	DS DP	I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799	007	7084245	May 12, 2024	DS DP U-1238		
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799	008	7084245	May 12, 2024	DS DP U-1238		
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001					>A> NC	Jul 17, 2015
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002					>A> NC	Jul 17, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003					>A> NC	Jul 17, 2015
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004					>A> NC	Jul 17, 2015
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREGABALIN - LYRICA</u>						
N021446 001	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 002	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 005	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 006	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 007	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 008	>A> 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N022488 001	>A> 6001876	Dec 30, 2018	U-819	Y		
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	>A> 4977138	Aug 22, 2013	DS DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	>A> 6740669	Nov 14, 2022	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	8168637	Jun 26, 2022	DP U-1188			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8118771	Aug 10, 2023	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001					NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		ODE	May 30, 2014
	8026276*PED	Jul 20, 2026			PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 004	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-999	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-248	Y	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-250	Y	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002					NCE	Nov 10, 2015
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N020763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	>A> 6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	>A> 6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	>A> 6455557	Nov 28, 2021		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	>A> 8211880	Mar 10, 2029			U-1258	
	>A> 8211880	Mar 10, 2029			U-1257	
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					>A> ODE	Feb 20, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022			U-839	
	>A> 8236804	Jun 05, 2022			U-839	
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022			U-839	
	>A> 8236804	Jun 05, 2022			U-839	
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022			U-839	
	>A> 8236804	Jun 05, 2022			U-839	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001					NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>